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Once upon a time there was a tale of a ketchup bottle.
You open it and first nothing comes out.
But if you are patient and try long enough, the ketchup starts running.
And then there will be plenty.
But what the tale did not tell us
is that sometimes it is best to open another bottle.
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6ABSTRACT
In the beginning of the 21st century, the development of next generation sequencing
(NGS) methods revolutionized the discovery of novel viruses and laid the foundations of
a new era in virology. With NGS, the amount and quality of sequence data increased
tremendously, and the decreasing price made large-scale screening possible. As a result,
hundreds of novel viruses have been identified, and especially the number of novel small
DNA viruses, including parvoviruses, has grown substantially.
This thesis consists of studies of three novel parvoviruses, bufavirus (BuV), tusavirus
(TuV), and cutavirus (CuV). All three viruses were originally identified by NGS from the
diarrheal feces of children between 2012 and 2016, and they were the first viruses in the
Protoparvovirus genus putatively infecting humans. Many of the animal viruses in this
genus are known pathogens: for example, canine parvovirus (CPV) can cause severe
gastroenteritis with high mortality among puppies. Currently, there are three genotypes
of BuV and one genotype each of CuV and TuV. BuVs have been detected mainly in fecal
samples, whereas CuV DNA has been detected in skin biopsies of cutaneous T-cell
lymphoma (CTCL) and melanoma patients as well. Any findings of TuV have been rare.
Here, we developed diagnostic methods for detecting viral DNA and IgG antibodies
against BuV1-3, TuV and CuV, and analyzed 4300 samples from 11 cohorts on four
continents to determine the epidemiology and potential clinical impact of these viruses.
The BuV DNA was detected in diarrheal fecal samples from both adults and children
in Finland, although with low prevalence. In addition, one nasal swab harbored BuV DNA.
These studies were among the first to show BuV circulation in Europe and among adults,
and further, the nasal swab is still the only non-fecal human sample containing BuV DNA.
Although we detected BuV exclusively in diarrheic feces, our results did not strongly
support a major role of BuV in gastroenteritis.
One of the main findings in this thesis was the remarkable difference observed in the
BuV seroprevalence between different populations: in the Middle East and Africa, the
BuV IgG antibodies were detected in 56-85% of the adult population whereas in Finland
and in the USA the seroprevalence was very low, <4%. This indicated that Iraq, Iran and
Kenya are endemic areas for BuV. In addition to the seroprevalence difference, the
predominant BuV type varied: it was BuV1 in the Middle East and BuV3 in Kenya. In
Kenya, an age-dependent increase in BuV seroprevalence in children was apparent, and
it seems that BuVs are not infecting young children in particular. The next important step
in BuV studies will be identifying patients with acute primary infection to elucidate the
symptoms and clinical picture of the infection. Our data on the geographical distribution
of BuVs will help defining suitable locations for such studies.
In contrast to that of BuV, the CuV seroprevalence was low in all populations analyzed.
Therefore, it is interesting that CuV DNA was detected significantly more often in the
lesional skin biopsies from CTCL patients in Finland than in those of transplant patients
7or healthy adults. This indicates that there is an association between the CuV DNA
presence and CTCL, however, it is not known whether this association is causal, accidental
or something else. The analysis of additional skin biopsies from the CuV DNA-positive
patients revealed CuV DNA in every available skin sample, including both healthy and
malignant tissue. Furthermore, lymph nodes harbored CuV DNA, while the prostate
samples were CuV negative. Serological analysis of archived serum samples showed that
the patients with CuV DNA in the skin had CuV IgG-antibodies already 5-21 years before
the skin biopsies were taken. This suggests that CuV can persist for decades after primary
infection similarly to human parvovirus B19. However, even if some preliminary disease
associations exist, the role of CuV in CTCL or other skin cancers needs further
investigations.
TuV findings, both DNA and antibodies, were absent or scarce. TuV DNA was not
detected in any of the skin tissues, and TuV IgG was detected only in one child and one
transplant patient among the serum samples of 1500 individuals ranging four continents.
Overall, more studies are needed to confirm if TuV truly is a human virus or just
accidentally occurring in human samples.
8TIIVISTELMÄ
Vuosituhannen vaihteessa menetelmät syväsekvensointiin ja virusten rikastamiseen
kehittyivät suurin harppauksin ja uusien virusten löytäminen erilaisista
näytemateriaaleista helpottui merkittävästi. Tämä johti uuden aikakauden alkamiseen
virologiassa, kun lukuisia uusia viruslajeja ja jopa aiemmin tuntemattomia virusheimoja
tunnistettiin. Varsinkin pienten DNA-virusten, kuten parvovirusten, määrä on kasvanut
merkittävästi.
Tässä väitöskirjassa tutkittiin kolmea uutta parvovirusta, bufavirusta (BuV),
tusavirusta (TuV) ja cutavirusta (CuV), jotka kaikki löydettiin syväsekvensointi-
menetelmillä lasten ripuliulosteesta vuosina 2012-2016. Ne olivat ensimmäisiä ihmisiä
infektoivia viruksia Protoparvovirus-suvussa. Suvun muiden, eri eläinlajeja infektoivien
virusten tiedetään aiheuttavan vaarallisiakin tauteja. Näihin kuuluu esimerkiksi koiran
parvovirus, joka aiheuttaa vakavia ripulitauteja ja johon liittyy korkea kuolleisuus
pennuilla. Tällä hetkellä BuV:sta tunnetaan kolme genotyyppiä ja CuV:sta ja TuV:sta
molemmista yksi. BuV:ta on havaittu lähes yksinomaan ulostenäytteissä eri puolilla
maailmaa, kun CuV DNA:ta on löydetty myös syöpäpotilaiden ihonäytteistä mm.
kutaanista T-solulymfoomaa (cutaneous T-cell lymphoma, CTCL) ja melanoomaa
sairastavilta potilailta. TuV löydökset ovat olleet harvinaisia. Tässä väitöskirjassa
pystytimme diagnostisia menetelmiä BuV1-3-, TuV- ja CuV-DNA:n sekä vasta-aineiden
havaitsemiseen ja analysoimme 4300 näytettä yhdestätoista eri kohortista neljältä eri
mantereelta selvittääksemme näin uusien virusten epidemiologiaa ja kliinistä merkitystä.
Löysimme BuV DNA:ta suomalaisten ripulipotilaiden ulosteesta sekä aikuisilta että
lapsilta, joskin esiintyvyys oli hyvin matala. Virusta löytyi myös yhdestä nenästä otetusta
näytteestä. Vaikka tulokset eivät viitanneet siihen, että BuV aiheuttaisi gastroenteriittejä
ainakaan laajassa mittakaavassa Suomessa, tutkimuksemme olivat ensimmäisiä, jotka
osoittivat BuV:n kiertävän Euroopassa ja että BuV-DNA:ta löytyy myös aikuisten
näytteistä. Lisäksi nenän pyyhkäisynäyte on edelleen ainoa näyte, jossa BuV DNA:ta on
tavattu ihmisissä muualla kuin ulostenäytteessä.
Eräs väitöskirjan päätuloksista oli havainto BuV IgG-vasta-aineiden yleisyyden
suuresta vaihtelusta eri väestöissä: Suomessa ja USA:ssa vain muutamalla prosentilla
aikuisista oli vasta-aineita, kun Irakissa, Iranissa ja Keniassa jopa 85% aikuisväestöstä oli
BuV-IgG-positiivisia. Lähi-Itä ja Afrikka näyttävätkin olevan BuV:n kotoperäistä aluetta,
BuV1:n ollen yleisin virustyyppi Lähi-Idässä ja BuV3:n Keniassa. Lisäksi havaitsimme,
että BuV-IgG-seroprevalenssi kasvoi lapsilla iän myötä ja tulos viittaa siihen, etteivät
bufavirukset infektoi erityisesti pieniä lapsia, vaan kaiken ikäisiä. Seuraava tärkeä askel
BuV-infektion tutkimuksissa on löytää potilaita, joilla on akuutti infektio, ja näin taudin
oireita ja kliinistä kuvaa voidaan selvittää. Tuloksemme viruksen maantieteellisestä
jakautumisesta helpottavat jatkotutkimusten suuntaamista alueille, joissa akuutteja
infektioita todennäköisesti esiintyy.
9Päinvastoin kuin BuV:n kohdalla, CuV:n IgG-seroprevalenssi oli matala kaikissa
tutkituissa maissa ja eri potilasryhmissä. Siksi olikin mielenkiintoista, että löysimme CuV
DNA:ta merkittävästi useammin CTCL-potilaiden syöpänäytteistä kuin
elinsiirtopotilaiden tai terveiden aikuisten ihonäytteistä. Muita kudosnäytteitä
analysoitiin kolmelta CuV DNA-positiiviselta potilaalta, ja CuV DNA:ta löytyi kaikista
ihonäytteistä riippumatta siitä, oliko näyte terveestä vai sairaasta ihosta. Lisäksi CuV
DNA:ta havaittiin imusolmukkeissa, mutta eturauhasnäytteet olivat negatiivisia.
Arkistoituja seeruminäytteitä tutkimalla pystyimme osoittamaan, että CuV DNA-
positiivisilta henkilöltä löytyi CuV IgG-vasta-aineita jopa 21 vuotta ennen ihonäytteen
ottamista. Näin ollen on hyvin todennäköistä, että CuV on säilynyt elimistössä
vuosikausia akuutin infektion jälkeen samankaltaisesti kuin ihmisen parvorokkovirus
(B19V).
Erot CuV:n esiintyvyydessä eri potilasryhmien välillä olivat tilastollisesti merkittäviä
ja tulos viittasi siihen, että CuV:lla voisi olla jokin rooli CTCL:ssä. Tulokset eivät
kuitenkaan kerro, oliko CuV taudin syy, seuraus vai oliko virus sattumalta näissä
kudoksissa. Tarvitaankin lisää tutkimuksia, jotta CuV:n merkitys CTCL:ssä ja muissa
ihon syövissä selviää.
TuV löydökset olivat harvinaisia. Emme löytäneet TuV DNA:ta yhdestäkään
ihokudoksesta ja vasta-aineita havaitsimme vain yhdellä lapsella ja yhdellä aikuisella
elinsiirtopotilaalla. Näin ollen jää edelleen vahvistamatta, onko TuV oikeasti ihmisen
virus vai löytyykö virusta vain satunnaisesti ihmisistä, joihin virus on joutunut
vahingossa.
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ABBREVIATIONS
aa amino acid
AAP assembly activating protein
AAV adeno-associated virus
AGE acute gastroenteritis
AIDS acquired immune deficiency syndrome
ARTI acute respiratory tract infection
B19V human parvovirus B19
BHQ Black Hole Quencher
BKV human polyomavirus BK
bp base pair
BPV bovine parvovirus
BuV human bufavirus
cap capsid protein, used with AAVs instead of VP
CPV canine parvovirus
CTCL cutaneous T-cell lymphoma
CSN central nervous system
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CuV human cutavirus
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EIA enzyme immunoassay
EM electron microscopy
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ETS epitope-type specificity
FFPE formalin-fixed, paraffin-embedded
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GT genotype
H-1PV rat protoparvovirus H-1
H5 HighFive insect cells
HAART highly active antiretroviral therapy
HBoV human bocavirus
HBoV1 human bocavirus 1
HBoV2 human bocavirus 2
HBoV3 human bocavirus 3
HBoV4 human bocavirus 4
HCV hepatitis C virus
HIV human immunodeficiency virus
IBD inflammatory bowel disease
ICTV International Committee on Taxonomy of Viruses
IgG immunoglobulin G
IgM immunoglobulin M
ISH in situ hybridization
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IU international unit
JCV human polyomavirus JC
kb kilobase
kDa kilodalton
MF mycosis fungoides
mORF putative short middle protein
MVC minute virus of canines
MVM minute virus of mice
mRNA messenger ribonucleic acid
neg negative
NGS next generation sequencing
nm nanometer
nPCR nested PCR
NP1 nuclear phosphoprotein 1
NPS nasopharyngeal sample
NS non-structural gene or protein
NS1 non-structural protein 1
NS2 non-structural protein 2
nt nucleotide
OD optical density
ORF open reading frame
p5 HBoV promoter
p6 B19V promoter
PARV4 human parvovirus 4
PCR polymerase chain reaction
p.i. post-infection
PLA2 phospholipase A2
pos positive
PPV porcine parvovirus
qPCR quantitative polymerase chain reaction
rep replication initiator protein, used with AAVs instead of NS
RNA ribonucleic acid
SAT small alternatively translated protein
SIV simian immunodeficiency virus
ssDNA single-stranded DNA
TuV human tusavirus
tx transplant
VLP virus like particle
VP virus (capsid) gene or protein
VP1 virus (capsid) protein 1
VP1u VP1 unique N-terminal end
VP2 virus (capsid) protein 2
VP3 virus (capsid) protein 3
VR variable region (in the capsid)
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PREFACE
The development of next-generation sequencing (NGS) and metagenomics revolutionized
the discovery of novel viruses and laid the foundations of a new era in virology. Whereas
in the 20th century novel human viruses were mainly discovered by tedious, demanding
and often biased methods such as cell culture or electron microscopy (EM), in the 21st
century the sequence-independent amplification and NGS enabled detecting unknown
viruses in a fast and straightforward manner. As a result, hundreds of novel viruses have
been identified, and especially the number of novel small DNA viruses, including
parvoviruses, has grown substantially. One common feature these small viruses share is
that they grow poorly if at all in commonly used cell cultures. In addition, the capsid
structure is often very stable and preserves the viral DNA both in the samples as well as
during the virus enrichment steps often used prior to NGS.
The one big advantage cell culture has over NGS is the isolation of the novel virus
itself. In comparison, when the virus is identified with NGS, it is only a sequence on a
computer, and no knowledge of the infectivity, pathogenicity or structure of the virus is
obtained. Neither is it known, whether the detected viral sequences are derived from an
infection of the individual or if the sequence even is that of a true virus. Thus, NGS is only
the first step in the process and further studies are needed to describe the virus, its
biology, epidemiology as well as the clinical picture of the infection.
Regarding this thesis, the previous sentence sums up the purpose and aim of the
project. The starting point was the novel putative human protoparvoviruses detected by
NGS, and the thesis describes the diagnostic methods and the sample analysis that were
carried out in order to elucidate the properties of these novel parvoviruses.
The literature review focuses on the overall properties of parvoviruses as well as on
the specifics of the pathogenic human parvoviruses, human parvovirus B19 (B19V) and
human bocaviruses (mainly HBoV1). The currently used parvovirus diagnostics is also
described. An introduction to the novel human protoparvoviruses is given although more
detailed information is available in the results and discussion part of this thesis.
Review of the literature
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1 REVIEW OF THE LITERATURE
1.1 OVERVIEW OF PARVOVIRUSES
Parvoviruses are small (21-28 nm), non-enveloped, single-stranded DNA (ssDNA) viruses
that infect various animal species ranging from insects, crustaceans and starfishes to
humans and numerous other mammals. The name “parvo” derives from the Latin word
parvus meaning small, and it was introduced in 1966 to describe these small DNA
viruses1. In general, parvoviruses are host specific and require rapidly dividing cells as the
short 4-6 kb genome codes only for a few major proteins: non-structural proteins (NS or
rep) on the left side and structural proteins (VP or cap) on the right side of the genome2.
Although parvoviruses rely heavily on the host cell machinery and utilize for example the
host DNA polymerase(s), these viruses replicate autonomously, except the members of
the Dependoparvovirus, which need a helper virus.
Taxonomy of the parvoviruses. The parvovirus study group within the International
Committee on Taxonomy of Viruses (ICTV) has set up demarcation criteria for
distinguishing the viruses in the Parvoviridae family further into subfamilies, genera and
species, and currently, in January 2020, the classification is made based on the NS1
sequence. The two sub-families, Parvovirinae and Densovirinae2, are divided primarily
based on the host that the viruses infect (vertebrates vs. invertebrates, respectively),
although this distinction is largely, but not perfectly, supported by the phylogeny of the
NS1 protein sequence. A parvovirus genus is formed when the viruses are monophyletic
and share ≥30% of the NS1 amino acid (aa) sequence, while viruses that share >85% of
the NS1 aa sequence are considered to be one species2. Based on these criteria, the two
parvoviral subfamilies are divided into 13 genera with over 75 species (in Jan 2020).
The Parvovirinae subfamily consists of eight genera (Fig. 1), and human infecting
parvoviruses have been detected in five: Erythroparvovirus (human parvovirus B19
[B19V]), Dependoparvovirus (adeno-associated viruses [AAVs]), Bocaparvovirus
(human bocaviruses [HBoV1-4]), Tetraparvovirus (human parvovirus 4 [PARV4]), and
Protoparvovirus (bufavirus [BuV], tusavirus [TuV] and cutavirus [CuV])2. The subfamily
Densovirinae is divided into five genera: Ambidensovirus, Iteradensovirus,
Brevidensovirus, Hepandensovirus, and Penstyldensovirus2.
Until recently, all identified parvoviruses have followed the “rule” that viruses within
Parvovirinae infect only vertebrates and viruses in Densovirinae infect invertebrates.
However, a rapidly growing number of distinct parvoviruses have been identified that
infect vertebrates, e.g. reptiles, mammals, and birds, but cluster phylogenetically with
densoviruses, and therefore, the formation of a third subfamily* has been suggested2,3.
*In March 2020 the ICTV accepted the revised taxonomy for the family Parvoviridae including a third subfamily,
named Hamaparvovirinae. Pénzes et al. Arch Virol. 2020 Jun 12. doi: 10.1007/s00705-020-04632-4
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Figure 1. Phylogenetic relationships of the different genera within the Parvoviridae
subfamily. The phylogeny is based on NS1 amino acid sequence and follows the ICTV
demarcation criteria valid on January 2020. Reproduced and modified from Cotmore et
al.2 with permission.
Review of the literature
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Genome structure. The short ssDNA genome of parvoviruses consists of two major
open reading frames (ORFs), NS and VP, and at both ends of the genome there are
terminal hairpin structures, which are either homo- or heterotelomeric, i.e. identical or
different, depending on the species (Fig. 2). Most parvoviruses code also for smaller
ancillary proteins that utilize usually alternate or overlapping ORFs for transcription.
Such include nucleoprotein 1 (NP1) of the ave- and bocaparvoviruses4, assembly
activating protein (AAP) of the dependoparvoviruses5 and the small alternatively
translated protein (SAT)6 and NS2 of the amdo- and protoparvoviruses7–9 (Fig. 2).
Figure 2. Genome structure of parvoviruses in different genera within the Parvovirinae
subfamily. Genomes of the type species of each genus are shown as a single line with
terminal hairpin structures. The hairpins are scaled approximately 20× relative to the rest
of the genome. The ORFs encoding proteins are illustrated with boxed arrows: the green
arrows represent nonstructural NS proteins, the blue arrows the capsid forming VP
proteins and the yellow arrows the smaller ancillary proteins. Transcriptional promoters
are indicated by solid arrows and polyadenylation sites by the AAAAA. AAV, adeno-
associated virus; B19, human parvovirus B19; BPV, bovine bocavirus; MVM, minute virus
of mice. Reproduced from Cotmore and Tattersall 201410 with permission.
The NS1 is a non-structural replication initiator protein that has both endonuclease
and DNA helicase domains, whereas the roles of the often genus-specific ancillary
proteins are versatile and not fully elucidated for all viruses. NS1 is considered most
conserved as it is indispensable for the viral replication, and therefore the phylogenetic
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classification of parvoviruses is made based on the NS1 sequences2. The parvovirus capsid
protein is coded by a single gene in the right-hand side of the genome that includes the
entire VP1 sequence. The same ORF encodes also shorter VP2 or VP3 proteins, which are
truncated forms of VP1 with identical C-terminal sequence. With most parvoviruses the
VP1 unique N-terminal end (VP1u) contains a phospholipase A2 (PLA2) domain, a
calcium binding loop, and a nuclear localization signal.
Replication. In general, parvoviruses need rapidly dividing cells for replication as they
cannot drive the cells into S phase. This also limits the cell types parvoviruses can replicate
in, and many parvoviruses have very specific host cells in which they optimally grow in.
The replication is carried out in the nucleus with the rolling hairpin mechanism utilizing
the terminal hairpins as primers10,11, and the single-stranded genomes are packaged into
the ready-made capsid. Parvoviruses with identical terminal repeats, for example B19V
(Fig. 2), encapsidate both minus and plus strands in equal moiety (in separate capsids),
whereas the viruses with heterotelomeric hairpins, for example minute virus of mice
(MVM, Fig. 2), encapsidate predominantly the negative sense strand10. All virions,
regardless of the polarity of the packaged strand, are considered infectious, however, this
not been studied.
Structure. The capsid consists of 60 copies of the VP proteins, which form a structure
with T=1 icosahedral symmetry. The major capsid protein is the shortest, VP2 or VP3, and
usually there are only 5-10 copies of the VP1 in the native viral capsid10,12,13. In vitro the
shorter proteins can form the capsid alone, whereas VP1 cannot, and this shows that the
C-terminus is responsible for the capsid assembly14. The mature viral particle does not
contain any lipids or carbohydrates, and therefore the structure is very stable:
parvoviruses tolerate elevated temperatures as well as a wide range of pH conditions, and
they are resistant to many disinfectants2,15.
The capsid structure of approximately 100 parvoviral particles have been published,
including the X-ray crystallographic and cryo-EM studies with both capsid structures
alone and together with receptors or antibodies13. In all defined structures, the VPs form
a highly conserved core of an eight-stranded anti-parallel β-barrel motif (Fig. 3). Another
conserved structure is an α-helix located between βC and βD strands (Fig. 3). The surface
loops are located between the β-strands, and these loops contain the variable regions
(VRs), which have the highest sequence and structural diversity between parvoviruses.
The 60-mer capsid is assembled with 2-, 3-, and 5-fold symmetry-related interactions
(Fig. 4). The icosahedral 2-fold axis has a preserved depression among parvoviruses,
while the 3-fold protrusions vary. At the 5-fold axis, five β-barrels form a cylindrical
channel that has been proposed to be utilized for VP1 externalization during infection as
well as for genome packaging.
Review of the literature
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Figure 3. Common features of parvovirus VP monomer structure exemplified by canine
parvovirus (CPV) VP monomer. The grey box arrows depict the eight β-strands in the
conserved β-barrel motif (labeled βA to βI), and the red serpentine depicts the conserved
α-helix. Surface loops contain the highest variability between different parvoviruses (see
Fig. 8 for some examples of the loop differences between selected parvoviruses). The
icosahedral axis locations for 2-fold (oval), 3-fold (triangle), and 5-fold (pentagon) as well
as N- and C-termini are indicated (see Fig. 4 for a symmetry diagram illustrating the
positions of the icosahedral symmetry axes on the capsid surfaces). Reproduced from
Mietzsch, Pénzes and Agbandje-McKenna 201913 with permission.
The structural studies have demonstrated that the capsid structures are more
conserved than the protein sequences would suggest, and that even the variable regions
have similar topologies among parvoviruses (Fig. 4)13,16,17. For example, B19V and minute
virus of mice (MVMp) share only 14.5% VP2 sequence identity, whereas the structural
similarity is 41.5%13. In the defined structures, only capsid forming part of the VP (VP2 or
VP3) has been resolved, whereas the structure of the flexible VP1 N-termini (VP1u) is
unknown. With most parvoviruses the VP1u is believed to be positioned inside the capsid
and not affect the capsid structure. The flexibility is associated to the cluster of glycines
present close to the N-terminal end of the major VP, and this disordered glycine-rich
region is present among most species in the Parvovirinae subfamily.
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Figure 4. Capsid structures of selected parvoviruses in the Parvovirinae subfamily. The
capsids are viewed from the 2-fold axes and colored according to radial distance as
indicated by the scale bar (from blue [inside] to red [outmost parts]). AAV, adeno-
associated virus; B19, human parvovirus B19; BPV, bovine bocavirus; BuV, human
bufavirus; CPV, canine parvovirus; HBoV, human bocavirus; MVMp, minute virus of mice;
PPV, porcine parvovirus. Reproduced from Mietzsch, Pénzes and Agbandje-McKenna
201913 with permission.
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1.2 HUMAN PARVOVIRUSES
1.2.1 HISTORY OF HUMAN PARVOVIRUSES
The story of parvoviruses started in 1959, when Kilham and Olivier published their
findings considering a small and stable virus isolated from experimental rat tumors18. The
virus was later named Kilham rat virus, and during the next decade, several related
viruses were isolated from different laboratory rodents. In 1965 similar small viruses were
detected with electron microscopy as contaminants of a rhesus monkey kidney cell culture
infected with the simian adenovirus SV1519. Although these particles were defective
viruses and capable of replication only in the presence of simian or human adenoviruses,
they were believed to be true viruses19. The virus was named adeno-associated virus
(AAV), and it is considered the first identified human parvovirus.
Ten years later in 1975 human parvovirus B19 (B19V) was discovered20. As human
parvoviruses do not grow easily or at all in the commonly used cell culture systems or in
animal models, it is not surprising that the discovery of B19V was a coincidence like the
discovery of AAV: B19V caused a false reaction in a hepatitis B virus antigen test in blood-
donor screening20. Whereas AAV is in general regarded as non-pathogenic, B19V has been
shown to cause several diseases and symptoms such as a childhood rash disease erythema
infectiosum and acute joint pain similar to that of arthralgia and arthritis. More severe
complications include chronic anemia in the immunocompromised, and miscarriage and
fetal death during pregnancy. During the next three decades no other human-infecting
parvoviruses were identified, and thus it was believed that B19V is the sole pathogenic
human parvovirus.
However, that view changed in 2005. In the early 2000s, novel methods for large-
scale screening of previously unidentified viruses were developed, which facilitated the
start of active virus hunting21. These methods included virus enrichment and sequence-
independent amplification followed by cloning and sequencing22,23, although the last
steps were fairly soon substituted by next-generation sequencing and metagenomics.
Using these techniques, two research groups independently described two novel
parvoviruses in human samples in 2005: i) human parvovirus 4 (PARV4) was identified
in a serum sample of an intravenous drug user with acute infection symptoms, and ii)
human bocavirus 1 (HBoV1) was identified in nasopharyngeal aspirates of children with
respiratory symptoms23,24.
When the first sequence of a novel virus is described, the closely related viruses are
often detected soon after. This happened also with PARV4 and HBoV. Another PARV4
type, PARV4 genotype 2 (originally named PARV5), was detected in human plasma pools
in 2006 and a third genotype in bone marrow and lymph nodes in 200825,26. For HBoV,
three additional HBoVs, HBoV2-4, were discovered from fecal samples of diarrheic
children between 2009 and 201027–29. However, whereas the PARV4 genotype sequences
resemble each other closely (only ~8% divergence on the nt level and ~3% on aa30–32),
and are thus genotypes, HBoV1-4 differ more and form phylogenetically two species:
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HBoV1 and HBoV3 as well as gorilla bocavirus belong to one species and HBoV2 and 4 to
the other species2,33. Currently HBoV1 is established as the causative agent for respiratory
tract infections. PARV4, on the other hand, has been studied for 15 years, but the clinical
relevance is still unknown (reviewed in 31).
Between 2012 and 2016 the trend of finding novel human parvoviruses continued,
and three more parvoviruses were identified by NGS: bufavirus (BuV), tusavirus (TuV),
cutavirus (CuV)34–36. All of them were detected in diarrheal feces of children, and they
were the first viruses putatively infecting humans in the Protoparvovirus genus. This
thesis describes the studies of BuV, TuV and CuV, and these viruses will be discussed in
detail in forthcoming chapters.
1.2.2 HUMAN PARVOVIRUS B19
B19V is the most widely known and studied human-pathogenic parvovirus, and when
clinicians or laymen talk about parvoviral infections in humans, they usually mean B19V
infections.
Genome structure and replication. The 5.6-kb ssDNA genome of B19V is very
typical of parvoviruses and the long inverted terminal repeats are identical to each other
(Fig. 2)37,38. Both minus and plus strands are encapsidated in equal numbers, i.e. half of
the mature virions contain minus strand and the other half plus strand38. The B19V
genome codes for non-structural NS1, capsid proteins VP1 and 2, as well as two short
proteins, 7.5 kDa and 11 kDa (most recent transcription map is presented in 39), of which
the latter has been shown to have a regulatory role in VP expression as well as in
apoptosis40. The protein expression is controlled by a single promoter, p6, which is
located between the left terminal repeat and NS1. The virus capsid consists of >90% of
VP2 and <10% of VP112, and the structure is similar to that of other parvoviruses (Figs. 4
and 8). Globoside (P-antigen) has been considered to be the primary receptor for B19V
with the α5β1 integrin and Ku80 as possible co-receptors41–43, however, a recent study
showed that globoside is not needed during B19V cell entry44. Instead, globoside was
crucial for the NS1 transcription, and consequently the lack of globoside blocked the B19V
genome replication and capsid protein expression, which explains the resistance to B19V
infection in the individuals lacking globoside44,45.
Overall, B19V has a very narrow host cell tropism, it replicates only in the erythroid
progenitor cells (EPCs) in the bone marrow46,47. Besides the EPCs, B19V can enter several
other cell types, however, productive infection does not take place. This entry can be
helped with antibodies, and the uptake has been shown occur through antibody-
dependent enhancement (ADE) in monocytes, endothelial cells, and B cells48–50.
Interestingly, after the primary infection, B19V DNA remains in tissues, for example
in skin and in synovia51–53, and can be detected with sensitive PCR methods for decades
or even life long after the acute infection53. The mechanism for the persistence is not
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known, however, long-lived B cells have been suggested be one cellular site for the tissue
persistence50.
Genotypes of B19V. The B19V strains can be divided into three genotypes (GTs), which
differ from each other approximately 10% in the coding region (at the nt level)54,55. GT1 is
the prototypic virus and is currently the predominant virus circulating worldwide56–59.
The two other genotypes are rare: GT2 is mainly found in tissues and only sporadically in
blood53,55,60,61, and GT3 has been described to be endemic in Ghana and Brazil and
occasionally found in India and Turkey57–59,61. Interestingly, based on the GTs detected in
skin and other tissues of people from different age groups, the data suggest that GT1
replaced GT2 as the main circulating GT in the 1970s50,53,62: In the study by Norja et al.,
GT1 DNA was detected in skin samples of all age groups, whereas GT2 DNA was present
only in persons born 1973 or earlier53. The change in the GT was further shown in a study
by Toppinen et al., in which the remains of putative Finnish casualties from World War
II soldiers harbored B19V genotypes 2 and 3, but not of genotype 162.
Clinically or serologically there is no difference between the three GTs. The symptoms
described for GT2 and GT3 infections are identical to GT1, and in addition, cell culture
experiments have shown similar results63. Serologically the three genotypes have been
cross-reactive63–65, although in one study a commercial IgG EIA assay utilizing GT1
antigen failed to detect a portion of GT3 IgG-positive samples57.
Clinical aspects. B19V has been shown to be the etiological agent in several diseases
and the causality has been established in various, well-defined studies, including
experimental B19V infections of healthy adult volunteers66.
B19V is transmitted mainly through the respiratory route, but infection can be
acquired also through contaminated blood products67,68 or transplacentally from mother
to the fetus69. During acute infection, B19V DNA is first detected in the upper airways and
then a high-titre viremia (>1E+10 viral copies per ml serum) follows66. The viral load then
rapidly decreases; however, a low-level viremia can persist for months or years. B19V
infection elicits a strong humoral response that starts with IgM antibody 1-2 weeks post-
infections (p.i.) and is followed by IgG (Fig. 5)66. IgM is responsible for clearing up the
viremia and they last up to six months. IgG, on the other hand, prevails and provides life-
long immunity to B19V re-infection.
The most common disease caused by B19V is a childhood rash disease, called fifth
disease or erythema infectiosum70, although most infections are asymptomatic or mild.
In adults, arthritis is a common symptom of acute B19V infection71. In the study of
experimental B19V infection of healthy adults, two episodes with different symptoms
were observed: during high viremia (1-2 weeks p.i) fever and other non-specific symptoms
such as headache and itching occurred, and rash and arthritis were observed later (3
weeks p.i.), when the viremia had already been cleared and the antibody response
developed (Fig. 5)66.
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More severe symptoms of B19V infection are seen in patients with
immunosuppression or hematological diseases: persistent B19V infections may lead to
chronic anemia in immunocompromised patients72,73 and transient aplastic crisis may
occur in patients with hematological disorders such as sickle cell disease74,75.
The most devastating outcome of B19V infection can occur during pregnancy, when a
primary infection of the mother may result in hydrops fetalis and miscarriage or fetal
death, especially if the infection takes place during the first half of the pregnancy. The
seroconversion rate among pregnant women has been estimated to vary from 1.5% up to
13% during epidemic year76–79. However, transmission of virus to the fetus has been
estimated to occur in less than half of the cases80,81, and fetal loss is even less likely
(<10%)81,82. Moreover, if the baby is born alive, congenital abnormalities due to B19V are
rare83,84.
Occasionally B19V infection can lead to other severe diseases, such as pediatric
myocarditis, although these cases are rare. In addition, many studies have linked B19V to
various syndromes ranging from hepatitis and encephalitis to dermatological conditions
and chronic fatigue, however, the results are often controversial, strong evidence is
lacking, and in many cases the presence of B19V DNA due to the tissue persistence after
primary infection is not accounted for. For the interested reader, B19V related diseases
have been recently reviewed by Qiu et al.39.
1.2.3 HUMAN BOCAVIRUS 1-4
Human bocaviruses 1-4 were discovered between 2005 and 2010, and the sequences
showed similarity to the previously known bovine parvovirus (BPV) and minute virus of
canines (MVC) in the Bocaparvovirus genus. Soon after the discovery, evidence of the
role of HBoV1 in respiratory infections of children started to accumulate, while the role
of HBoV2-4 in still unknown.
Genome structure and replication. One full-length genome of HBoV1 has been
sequenced: it was 5543 nts long with non-identical hairpin structures in the ends of the
genome. Whereas B19V encapsidates both strands in equal amounts, 95% of the bocavirus
capsids contain the negative-sense genome85. HBoV utilizes one promoter, p5, and the
genome codes for four NS proteins (NS1-4), a unique NP1 protein, and three VP proteins
(VP1-3) of which VP3 is the major capsid protein39,86–89.
HBoV1 infects airway epithelial cells, and cell culture experiments have demonstrated
that HBoV1 can infect and replicate in the terminally differentiated cells90. Instead of
using the DNA-polymerases of cell DNA-replication, HBoV1 may be replicated by the
cellular DNA-repair DNA-polymerases, and thus the replication is cell cycle
independent90. The permissive cells or replication strategies for HBoV2-4 are not known.
Besides the genomic ssDNA form, HBoV1-4 DNA has been detected in episomal
forms91–94. Whether these circular dsDNA molecules are replication intermediates,
persisting forms of HBoV DNA or normal forms of enteric HBoV2-4 strains, is not known.
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Taxonomy of the four HBoVs. The NS1 and VP1/2 amino acid sequences of the four
HBoVs differ from each other 10.8-26.8% and 8.5-19.9%, respectively29, which is clearly
more than what the B19V genotypes differ from each other. The divergence of NS1 has
further consequences taxonomically: HBoV1 and HBoV3 as well as gorilla bocavirus
belong to Primate bocaparvovirus 1 and HBoV2 and 4 to Primate bocaparvovirus 22,33.
However, as the species classification does not follow the observed clinical picture of
HBoV infections nor the serological cross-reactivity between the four HBoVs, the species
naming has not been adopted in use21. In addition, HBoV3 clusters differently in the NS
and NP1 regions compared to the capsid protein region: on NS and NP, HBoV1 is the
closest relative of HBoV3, but in contrast, on VP, HBoV3 clusters with HBoV2 and
HBoV4. This separation was further backed up with full genome analyses, and therefore
it was suggested that HBoV3 could have originated from a recombination event between
HBoV1 and HBoV229. Similarly, HBoV4 was speculated to be a result from a HBoV2 and
HBoV3 recombination event, however, the analysis was based on a single HBoV4
sequence29.
Clinical aspects. Currently, HBoV1 is established as the causative agent of respiratory
tract infections, whereas HBoV2-4 are considered to have a more enteric role. HBoV1-3
are commonly detected, whereas HBoV4 is very rare (recently reviewed in 95).
The exact routes of infection of HBoV1-4 are not known, however, it has been
hypothesized that HBoV1, a respiratory pathogen, would be transmitted through the
respiratory route, whereas the possibly enteric HBoV2-4 would most likely utilize the
fecal-oral route95. In comparison to B19V, HBoVs have not been considered to be  threats
during pregnancy96,97, which is in line with the fact that nearly all adults are seropositive
and thus primary infections among pregnant women are rare. However, in a recent study,
HBoV DNA was detected in aborted fetal tissue and placenta, but whether the detected
DNA derived from an infection during pregnancy, could not be determined98. In addition,
discrepant results have been published of whether HBoVs present in blood products are
a cause for concern25,99,100.
HBoV1 infects mainly young children. During acute infection, the viral load in
nasopharyngeal samples (NPS) is high and the patients are viremic. After the acute phase
the viral DNA persists in the airways from weeks up to a year, and can thus be detected in
healthy children as well101. As a consequence, it has been estimated that only a quarter of
the children with HBoV1 DNA detected in the NPS actually have an acute HBoV1
infection102,103. HBoV2 and HBoV3 are detected mainly in fecal samples of children with
or without gastroenteritis, but viremia can occur.
IgM and IgG antibodies are elicited during HBoV infection, and the IgG antibody
response is long-lasting, but sometimes fluctuating103,104. HBoV1 seems to induce a
stronger IgG response than HBoV2 and 3103. The HBoV strains are highly cross-reactive,
which makes the analysis of virus-specific antibodies and serodiagnosis of an acute
infection more difficult. The correct analysis therefore requires the use of a competition
assay105. In addition, a phenomenon called “original antigenic sin” has been observed in
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HBoV infection: when a child is first infected with one HBoV strain, the secondary
infection with another HBoV strain does not induce specific antibodies towards the
second strain, but instead, the IgG of the primary HBoV strain is boosted106. How this
phenomenon affects the clinical picture of the secondary HBoV infections, is not known.
Nevertheless, HBoV infections are very common, which is demonstrated by the
prevalence of IgG antibodies in the population: over 90% of the less than 3 month-old
babies have been shown to have maternal IgG antibodies107, and by the age of six years
90-100% of the children had IgG of one of the HBoVs of which HBoV1 IgG is the most
prevalent103.
When using accurate diagnostic methods (see HBoV diagnostics), HBoV1 has been
shown to be an important respiratory pathogen in young children. The symptoms are very
similar to that of other respiratory viruses including common cold, cough, fever, rhinitis,
bronchiolitis, diarrhea, and wheezing. Besides the mild infections, HBoV1 can cause
severe lower respiratory tract infections and pneumonia requiring hospitalization, and
life-threatening cases or even death have been reported with HBoV1 as the sole infectious
agent95,108–114.
1.2.4 DIAGNOSIS OF HUMAN PARVOVIRUS INFECTIONS
In virus diagnostics one of the main questions has been the rationale of the entire testing,
if a potentially expensive test does not provide clinically useful information for the
clinician. However, nowadays there is a growing number of antiviral drugs available,
requiring the knowledge of the causative agent. In addition, the use of antibiotics can be
reduced by knowing that the infection is caused by a virus instead of a bacterium, and
accurate screening and diagnostics can also help controlling epidemics and directing
vaccine campaigns when a vaccine-preventable virus is causing an outbreak115. One
growing patient group, which benefit from the diagnosis of a wide range of virus
infections, are the immunocompromised individuals. For these patients normally less or
non-pathogenic viruses may become deadly, for example polyomaviruses BKV and JCV
in the case of transplant patients116,117.
In parvovirus diagnostics, serological testing of the patient’s serum is one of the main
approaches for achieving a useful diagnosis. Using IgM and IgG analyses the timing of the
infection can be deduced, which is often critical, for example in pregnant women with
B19V infection. Nucleic acid testing by quantitating the viral DNA or by measuring RNA
can also be used to pinpoint an acute infection, although prolonged parvovirus shedding
and viral DNA persistence complicate the interpretation of the PCR result.
To date, all human parvoviruses have been shown to induce antibody responses in
humans, and therefore serological assays could be useful tools to study the infections and
epidemiology of novel parvoviruses too. As the viremic phase, or the presence of viral
DNA in specific samples, might not correlate with the symptoms of the patients or with
the true acute infection, as seen with B19V and HBoV1, the results obtained from using
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solely PCR might not be conclusive. The course of a typical parvovirus infection with
viremia and antibody response is presented schematically in Figure 5.
Figure 5. Schematic view of typical human parvovirus infections. (A) depicts viremia followed
by antibody response, and (B) timing of symptoms and time frame of detecting DNA in
B19V and HBoV1 infections. See text for further information. NPS, nasopharyngeal swab.
B19V diagnostics. Acute infections of B19V are diagnosed mainly by analyzing the
patient’s serum sample for IgM and IgG antibodies. A high B19V DNA quantity in the
serum (>10E+06 copies per ml) also indicates acute infection, however, the viremic phase
with high titres usually precedes the symptoms and often the sample is taken too late. In
addition, after primary infection, B19V DNA persists in tissues and a low-level B19V
viremia can be detected in immunocompetent individuals118–120. Thus, the DNA-positivity
of a tissue or serum alone, especially when analyzed by qualitative PCR or when qPCR
shows a low viral load, is not a good marker for an acute infection. With
immunocompromised patients, the DNA testing might be the only option due to lack of
antibody formation, and with pregnant women, PCR coupled with antibody testing can
help in making the diagnosis.
The most reliable indicators for acute B19V infection are detection of IgM and
seroconversion or a 4-fold increase of IgG in paired serum samples. When only one serum
sample is available, the timing of the infection can be analyzed with IgG avidity, i.e. the
functional affinity of the IgG, or with epitope-type specificity (ETS) assays121–124. Both of
these assays utilize the different properties of early and matured IgG against B19V: in the
acute infection IgG antibodies to linear VP2 epitopes (peptides or linearized VP2) can be
detected and the IgG affinity to conformational VP2 (capsid) is weak, whereas later on the
IgG to linear epitopes disappear and the affinity of the IgG to conformational epitopes
increases.
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For ensuring the safety of blood products, the authorities in the USA have 
implemented regulations of the B19V-DNA load in plasma pools not to exceed 1E+04 
IU/ml (https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/blood-guidances 
and 125,126). In Europe similar recommendation apply. The cut-off was not set lower as 
the neutralizing B19V antibodies in the plasma pools are considered to protect the 
seronegative recipients from infection.
HBoV1-4 diagnostics. Diagnosing acute HBoV1 infections are more complicated than 
for B19V infections due to several reasons. Firstly, HBoV1 DNA can be detected in nasal 
secretions for months after the acute infection, and thus healthy individuals have HBoV1 
DNA in their samples101. HBoV1 has also been detected in fecal samples, however, it is 
not known whether HBoV1 caused GE or if the detected virus originates from 
the nasopharynx127,128. Secondly, the four HBoVs have strong cross-reactivity in 
serological assays, and it has been shown that prior immunity to one HBoV may 
hamper or even prevent the antibody response towards another HBoV103,106. Therefore, 
it is critical to use proper methods for HBoV primary infection diagnosis, and it is 
recommended that HBoV1 acute primary infection diagnosis should include at least two 
of the following: by qPCR, >10E+06 DNA copies per ml of NPS, mRNA or antigen 
detection in NPS, positive IgM, and low IgG avidity or seroconversion in follow up 
samples95.
The diagnosis of acute infections of HBoV2-4 is as complicated as of HBoV1 with 
viral DNA persistence and serologic cross-reactivity. No clear association of HBoV2 
and HBoV3 to GE or other diseases have been found, and the viral DNAs have been 
detected in stools of both patients and healthy individuals (recently reviewed in 95).
Competition assay for clarifying cross-reactive IgG EIA results. In HBoV 
diagnostics the serological cross-reactions of the four HBoVs greatly interfere with the 
result interpretation and a competition assay has been successfully employed to 
compensate for the cross-reactivities. Kantola et al. even stated that “Correction for 
cross-reactivity is a prerequisite for VLP-based HBoV seroepidemiology”105. In the 
competition assay homologous or heterologous antigens are incubated with the sample 
prior to the EIA, and only the specific antibodies not reacting with the common epitopes 
of the soluble antigen remain to be detected in the EIA. The result is then compared 
with the non-competed result. For example, when a sample is analyzed for HBoV1 IgG, 
the sample is analyzed in two adjacent wells with HBoV1 antigen bound to the well. In 
the first well, no competition is used, and in the second, the sample is incubated with 
HBoV2-4 antigens. The HBoV1 IgG-positive sample would give a positive result in both 
of the wells, while HBoV2-4 IgG positive samples would be negative in the second well 
due to the soluble HBoV2-4 antigens removing the antibodies.
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1.3 HUMAN PROTOPARVOVIRUSES
1.3.1 HUMAN BUFAVIRUS
Discovery of BuVs. In 2012 Phan and colleagues studied fecal samples from under 5-
year-old children with acute diarrhea in Burkina Faso in order to find novel enteric
viruses34. Rotavirus antigen-negative samples were subjected to viral-particle enrichment
and NGS, and sequences showing significant similarities to parvoviral proteins were
obtained from one sample. After filling the gaps between NGS-derived sequences by PCR
and the ends by RACE (Rapid Amplification of cDNA Ends), a nearly full-length genome
with complete open reading frames of NS1 and VP1 and VP2 of a novel parvovirus was
acquired (4921 nts, GenBank #JQ918261)34. The virus was named bufavirus 1-BF96 based
on the discovery place and sample code: Burkina Faso parvovirus type 1 strain 96.
In a subsequent PCR study, three more samples harbored BuV DNA giving the overall
prevalence of 4% (4/98)34. However, when the complete protein-coding regions of all four
strains were determined, one showed only 72% amino acid identity on the VP2 protein
compared to the other three, although the NS1 was >95% similar. Thus, a second BuV
type, BuV2, was proposed34. Two additional cohorts of fecal samples from children were
also analyzed with the same BuV nested PCR, and 1 of 63 (1.6%) in Tunisia (children with
nonpolio acute flaccid paralysis), but none of 100 in Chile (children with diarrhea),
harbored BuV DNA. This result showed that the novel virus was not geographically
restricted to Burkina Faso34.
Two years later in 2014, a third genotype, BuV3, was discovered in Bhutan in fecal
samples of diarrheic children with a prevalence of 0.8% (3/393)129. The BuV3 was nearly
identical to BuV1 and BuV2 in NS1 region with >95% similarity at both the nt and aa
levels, however, the VP region was more different with only ~73% similarity to the VP2 of
BuV1 and 65% to that of BuV2 (aa level). The VP2 of BuV3 had also 3 amino acids more
than BuV1 and BuV2129.
Genome and structure of BuVs. The genome of BuV has two major ORFs that encode
for the non-structural NS1 and the capsid proteins VP1 and VP2 (Fig. 6), with the lengths
of 672-674, 708-711, and 570-573 amino acids, respectively, depending on the
genotype130. The genome contains also an ATP- or GTP-binding Walker loop, two
Figure 6. Organization of the BuV genome. The illustration is based on BuV1 strain BF96
(GenBank no. JQ918261, 4912 nts). Amino acid alignment of the major NS and VP
proteins, the putative short proteins, middle ORF and SAT, as well as the theoretical
splicing of VP1 are shown34,36.
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conserved replication initiator motifs, PLA2 in the VP1 unique region, a glycine-rich
sequence in the VP2 N-terminal end, and the same splice sites. The three BuVs are nearly
identical in the NS1 (94-96% on aa), whereas the capsid is more divergent (VP1: 71-78%
on aa; VP2; 65-73% on aa). Besides the major ORFs, a third ORF has been identified in
the middle of the genome, and it codes for a smaller ~130 aa-long protein (Fig. 6). This
mORF does not share any similarity to other parvoviral proteins, however, the later
discovered animal BuVs and human CuV have similar short ORFs in their genomes131.
The ORF coding for small alternatively-translated protein (SAT), which is found in other
protoparvoviruses and amdoparvoviruses, was not originally reported for any of the
BuVs, however, Phan et al. describe such an ORF of 82-103 aa in the article reporting the
discovery of CuV36. Overall, all ORF and mRNA estimations have been made in silico and
await confirmation in cell culture experiments.
The capsid structures of the three BuVs have been determined by cryo-electron
microscopy, and the capsid surface morphology of the three BuVs were nearly identical
(Fig. 7). The 3D structure also resembled closely the morphology of the other parvoviruses
in the Parvovirinae subfamily and especially those in the genus Protoparvovirus (Figs. 4
and 8)132. The sequence similarity between BuV1 and the other protoparvoviruses was
only ~30%, while the structural similarity was ~75%. The biggest structural difference
was located in the 3-fold protrusions: an 11-aa deletion in the variable loop VIII of the
BuVs caused a formation of three separate protrusions, whereas in the classical
protoparvoviruses the 3-fold protrusions form a single pinwheel structure (Figs. 4, 7 and
8).
Figure 7. The capsid structures of BuV1, BuV2 and BuV3. The capsids are viewed from the 2-
fold axes and colored according to radial distance as indicated by the scale bar (from blue
[inside] to red [outmost parts]). The three separate protrusions are visible in the 3-fold
axes. Res., resolution. Reproduced and modified from Ilyas et al. 2018132 with permission.
BuV1 BuV2 BuV3
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Figure 8. The structures of BuV1 and selected parvoviruses. Stereo projection of the structural
superposition of VP monomers from (A) BuV1 and other protoparvoviruses, and (B) BuV1
and the human-infecting parvoviruses AAV, B19V and HBoV1. The VR regions (VR-I to
VR-IX) and the HI-loop are labeled. The 11-aa deletion that causes the 3-fold pinwheel
structural difference between the BuVs and the other protoparvoviruses can be seen in
the VR-VIII loop. (C) Radially-colored capsid structures of BuV1, MVMp and B19V,
coloring from blue to red as shown in Figure 7. AAV, adeno-associated virus; B19, human
parvovirus B19; BuV, human bufavirus; CPV, canine parvovirus; FPV, feline
panleukopenia virus; H-1PV, rat protoparvovirus H-1; HBoV, human bocavirus; HI-loop,
loop between βH and βI strands (see Fig. 3 for more info); LuIII, parvovirus LuIII; MVMp,
minute virus of mice; PPV, porcine parvovirus; VR, variable region. Reproduced and
modified from Ilyas et al. 2018132 with permission.
BuV1 MVMp B19V
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Phylogenetic analysis. Phylogenetically the three BuV genotypes belong to one
species, Primate protoparvovirus 1 as they are nearly identical in the NS1 protein
sequence. In the NS1 region BuVs are closest animal bufaviruses and the classical animal
protoparvoviruses that infect rodents, canines and porcines. However, the capsid proteins
of the three BuV genotypes are only 65-73% similar (VP2 aa)133, and in the phylogenetic
tree, they cluster in three different branches. In addition, the members of genus
Amdoparvovirus cluster between BuVs and the classical protoparvoviruses in the VP
region, and the Protoparvovirus genus seems to be divided (Fig. 9).
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Figure 9. Phylogenetic trees of NS1 and VP2 of selected human and animal protoparvo-
viruses, and amdoparvoviruses. Magenta circles denote BuV1, purple circles BuV2,
light magenta circles BuV3, turquoise triangles CuV, green circle TuV, empty diamonds
the classical protoparvoviruses, and black squares amdoparvoviruses. The phylogenetic
tree was based on nt sequences, and the trees were generated with the maximum
likelihood method and the general time reversible model with 1000 replicates using MEGA
7.0. The bootstrap values are shown if >75%134.
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BuV in human samples. To date, BuV DNA has been detected in fecal samples in
Africa, Europe, Asia, North America and South America with low prevalences of 0.3-8%
in both children and adults, as well as in surface water in Ecuador and Thailand (see Table
3 in Results and discussion). Overall, the findings during the first five years after the BuV
discovery (2012-2017) suggested that BuV might have a role in gastroenteritis as all BuV
DNA-positive patients had GE symptoms and the non-diarrheal controls were BuV-DNA
negative. On the other hand, BuV DNA was not frequently detected in any cohort, the viral
loads were low when reported, and the BuV DNA-positive samples often harbored a
known GE-causing pathogen. Since 2018, BuV DNA has been occasionally detected in
stools of healthy or non-diarrheal individuals135–137, but large-scale analysis of other
sample types than feces is still lacking. In addition, no patient with acute BuV infection
has been described in the literature and identifying such patients in the future will be
critical for defining the clinical picture of BuV infections. With B19V and HBoVs, it is well
established that the viral DNA persists for a long time after primary infection and that the
DNA of the respiratory HBoV1 can be detected also in fecal samples. Whether the same
phenomenon occurs also with BuVs, is not known.
Interestingly, the DNA of BuV1 and/or BuV3 has been detected in several studies
around the world, but DNA of BuV2 has been absent. The BuV2 DNA-positive sample
from first study identifying BuV in Burkina Faso is still the only sample with BuV2 DNA
described in the literature. However, feces, the sample type used in most studies, may not
be a good sample for detecting BuV2 DNA. In addition, there might be other issues with
BuV2 detection, for example assay specificity and sensitivity for BuV2 versus BuV1 and
BuV3 that hamper the detection.
1.3.2 HUMAN TUSAVIRUS
In 2014, a second novel protoparvovirus, tusavirus (TuV), was detected in human stool35.
Phan and coworkers analyzed fecal samples with metagenomic deep sequencing
combined with viral enrichment from infants and children with unexplained diarrhea in
Tunisia to find novel viruses potentially contributing to the illness. Although the 180
samples had been tested negative for rotavirus, norovirus, astrovirus, sapovirus,
adenovirus types 40 and 41, and Aichi virus by RT-PCR, many reads matching these
viruses were identified by deep sequencing, of which sapovirus was the most frequent35.
One pool showed a single read with similarity to the NS1 of rat parvovirus. The
individual sample containing the viral read was identified by PCR, and by further deep
sequencing and PCR, a nearly complete genome of a novel parvovirus (4 424 nt) was
acquired (Fig. 10). The virus was named tusavirus (Tunisian stool-associated parvovirus).
No other eukaryotic viral sequences were found in the NGS reads of the sample that could
explain the symptoms of the child, however, no testing optimized for pathogenic bacteria
or parasites was carried out. Nested PCR analysis of the other samples remained TuV
negative, and the overall prevalence of TuV in Tunisian children was 0.56% (1/180)35.
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Figure 10. Organization of the TuV genome. The illustration is based on strain Tu491 (GenBank
no. KJ495710, 4424 nts). Amino acid alignment of the major NS and VP proteins, as well
as the theoretical splicing of VP1 are shown35
Phylogenetically the Kilham rat parvovirus shares the highest identity to TuV (44% in 
NS1), and TuV clusters together with the classical animal protoparvoviruses, such as the 
mouse pathogen MVM and the canine pathogen CPV, instead of BuVs (Fig. 9). According 
to the genus and species demarcation criteria of the ICTV, TuV was proposed to belong to 
a novel species in the Protoparvovirus genus2,35, however the classification is still pending 
(in January 2020)2.
Since the discovery, TuV-like sequences have been described only in one article: 
partial sequences of 438-1519 bps matching 39-82% to TuV sequence were obtained by 
NGS in feces from fur seals in Brazil (see also Table 1, animal bufaviruses)138. Otherwise, 
the studies of TuV are limited to the ones included in this thesis, and it is still unknown 
whether TuV is a human virus.
1.3.3 HUMAN CUTAVIRUS
Discovery of CuV. Human cutavirus was discovered in 2016 by an identical process to 
that of the BuV and TuV: CuV sequence reads were identified with metagenomics in 
diarrheal fecal samples from children in Brazil36. Further prevalence studies were carried 
out with PCR, which revealed CuV DNA in fecal samples of 4/245 (1.6%) children in Brazil 
as well as in 1/100 (1%) children in Botswana.
Then the story of CuV changed. During previous years several metagenomics datasets 
had been generated from human, animal and environmental samples, and these data sets 
were screened for the novel CuV in silico36. Unexpectedly, one pool of skin biopsies from 
cutaneous T-cell lymphoma (CTCL) (n=2) and parapsoriasis (n=2) patients from France 
contained nearly identical sequences to CuV. PCR analysis of individual samples in the 
pool revealed CuV DNA in both of the CTCL tissues, while the parapsoriasis samples were 
negative. Both CTCL patients had mycosis fungoides (MF), the most common subtype of 
CTCL. In an additional PCR study, two more MF tissues were shown to harbor CuV DNA, 
whereas all other skin biopsies including ten skin carcinoma, eight parapsoriasis, eight 
eczema or eczematoid dermatitis and three healthy skin samples were negative for CuV 
DNA36. The presence of CuV in the MF biopsies was further confirmed with in situ 
hybridization showing CuV in 2/4 CTCL samples initially positive for CuV DNA. The ISH 
showed only a few, but highly positive cells harboring CuV36. Due to the link to CTCL, the 
virus was finally named cutavirus (cutaneous T-cell lymphoma associated parvovirus).
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Genome and structure of CuV. The genome of CuV has two major ORFs coding for
NS1 and VP1/2 as well as a shorter middle ORF and a SAT-like ORF (Fig. 11)36,139. BuV2
is phylogenetically the closest virus, sharing 76% similarity in NS1 and 82% on VP1. The
mORF of CuV is shorter than in BuVs and has only 45% similarity. The VP1u contains
PLA2 activity, and interestingly, the N-terminal end of VP2 shows the highest divergence
between the CuV strains (Fig. 12). The CuV capsid structure has not been determined,
however, due to the close sequence resemblance of CuV and BuV2 VP2s, the structure
could be hypothesized to be very similar132.
Figure 11. Organization of the CuV genome. The illustration is based on strain BR-337 (GenBank
no. NC_039050, 4456 nts). Amino acid alignment of the major NS and VP proteins, the
putative short proteins (middle ORF and SAT), as well as the theoretical splicing of VP1
are shown36. VP2 and SAT are translated in different frames.
Figure 12. Alignment of the first 50 amino acids in the N-terminal end of CuV VP2 protein. The
alignment contains all published CuV strains on January 2020. Although the entire VP2 is 
nearly identical between the CuV types (97% similarity on aa), most of the differences 
are located before the glycine-rich region. The first M in the alignment is the 
starting methionine of VP2. *, CuV from cancer biopsy; dot (.), identical aa compared to 
the upper sequence.
Phylogenetic analysis. Nearly full-length genomes with complete NS and VP ORFs
have been amplified from four patients: in a fecal sample of a Brazilian child, in CTCL
biopsies of two French CTCL/MF patients and in one Danish melanoma patient36,139.
Partial genomes, missing only the N-terminal end of NS1, were obtained from four other
children (three from Brazil, one from Botswana)36. The different strains have been very
similar to each other with 93-98% aa identity in NS1 and 96-99% in VP1, and it seems
that there is only one genotype of CuV so far140. Phylogenetic analysis showed that CuV
was closely related to human BuVs, however as the NS1 was only 76% similar on aa to the
closest human BuV, BuV2, a distinct protoparvovirus species was suggested. Currently
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CuV is classified to species Primate protoparvovirus 3 in genus Protoparvovirus by ICTV
parvovirus study group (as in January 2020)2.
Interestingly, although based on NS1, BuV1-3 and CuV are clearly different viruses,
the capsid protein region of CuV clusters with that of BuV2, while the VPs of BuV1 and
BuV3 cluster together. Furthermore, when comparing the phylogenetic trees of the entire
Protoparvovirus genus with that of the closest genus Amdoparvovirus, in the NS1 tree
the two genera are separate, whereas in the VP1 or VP2 trees amdoviruses are between
the classical protoparvoviruses and bufaviruses (including human and animal BuVs, and
CuV) (Fig. 9).
CuV in human samples. The finding of CuV DNA in cancerous tissue directed the
forthcoming studies towards skin biopsies from different patient groups instead of fecal
samples, as was the case with human BuVs. Only one additional study describing CuV in
fecal samples has been published: Siqueira et al. identified NGS reads matching CuV in 2
children from two isolated Amazonian villages in Venezuela135.
Currently CuV DNA has been detected in melanoma tumor biopsies in Denmark (1/10,
10%) and in Germany (2/179, 1.1%), in MF lesions in Germany (6/71, 8.5%) as well as in
skin swabs of healthy (9/237, 3.8%) and of HIV-positive men (35/205, 17.1%)139,141,142. In
one study from Italy, no CuV DNA was detected in CTCL skin samples (n=55), however,
the methods and value of this study published in an Italian journal are difficult to
interpret143.  Although Kreuter et al. detected CuV DNA only in MF lesions, and all other
studied cutaneous T-cell, NK-cell and B-cell lymphomas (n=59) were negative, more
studies are needed to determine to role of CuV in CTCL. In general, parvoviruses are not
oncogenic like some other viruses, but rather oncolytic such as the rat protoparvovirus H-
1 (H-1PV)144,145, which has been studies as a cancer therapeutic. Or parvoviruses might be
oncotropic as they need rapidly dividing cells for replication. In addition, B19V has been
shown to remain in skin tissue years or even decades after primary infection without
apparent harm or symptoms to the individual. CuV could show similar characteristics.
However, for a pre-disposed individual, such as immunocompromised or cancer patients,
a persisting virus might cause a disease.
1.4 ANIMAL BUFAVIRUSES
In October 2012, two months after the initial article describing human BuV, the first
animal BuV was identified146. Handley and coworkers studied the effect of the simian
immunodeficiency virus (SIV) infection to the enteric virome, enteropathy, and AIDS
progression in rhesus monkeys, and discovered a novel parvovirus resembling BuV2 (Fig.
9). The novel virus was named WUHARV parvovirus. By NGS and PCR analysis, viral
DNA was detected in the feces of ten SIV-infected rhesus monkeys (10/35, 28.6%) and in
one non-infected rhesus monkey (1/51, 1.9%)146. In addition, the same virus was present
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in the blood of four SIV-infected animals euthanized due to advanced AIDS146. Whether
the viremia was a result of a true systemic infection or that the virus had invaded the
enteric tissues and leaked into the blood stream as the immune system of the animals
were severely harmed by AIDS, cannot been concluded from this study. Further studies
are also needed to pinpoint the role of the virus in healthy rhesus monkeys. A control
group of 54 african green monkeys (29 SIV+, 25 SIV-) were all negative for the new virus.
During the following years several animal BuV-like viruses have identified in various
animal species around the world, both in wild and domestic animals. BuV-like viruses
were described in shrews and baboons in Zambia147, in bats in Hungary, China and
Indonesia148–150, in rats in China133, in domestic pigs in Austria, Hungary, and China151–
153, in sea otters in the USA154, and the most recently, canine BuV was detected in domestic
dogs in Italy,  Hungary and China as well as in domestic cats, wild wolves and wild foxes
in Italy155–159. In most cases these viruses have been searched for in fecal samples or in
rectal, nasal or oropharyngeal swabs, however, animal BuVs have been detected also in
the spleen of shrews, baboons, megabats, and sea otters, and in serum of dogs pointing to
systemic infections in these animals150,154,156,157. Phylogenetically the animal bufaviruses
cluster together with human BuVs and CuV, both in the NS as well as in the VP regions.
The causative role of BuVs in animal disease and possible symptoms in the infected
animals warrants further studies. In many of the published studies, animals have been
first screened for novel viruses by NGS, and then a prevalence study has been carried out
by PCR including the same animal cohort and occasionally some other animals. Although
the approach gives a good first impression of the prevalence of the virus and perhaps
directs future studies, the etiological role of these viruses in any disease cannot be reliably
assessed. In one study of dogs in Italy some correlation of canine BuV and a disease was
obtained: the presence of canine BuV DNA in the nasal and oropharyngeal swabs was
clearly associated with canine infectious respiratory disease (kennel cough)155. Overall,
the detection rates of the DNA of BuV-like viruses in the corresponding animals are higher
compared to BuV in human samples (Table 1).
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2 AIMS OF THE STUDY
This thesis project started when the first human protoparvovirus, BuV, was discovered in 
2012. The overall aim was to study the epidemiology and clinical relevance of this novel 
virus as well as to provide evidence of whether or not the virus is truly a human virus. The 
first specific aim of this thesis was
1. To set up a quantitative PCR (qPCR) method for analyzing BuV DNA in human
samples to elucidate the BuV occurrence in Finland
During Study I, the third genotype of BuV, BuV3, as well as another putative human
protoparvovirus, TuV, were described. These viruses were included in the studies, and the
next aims were
2. To clone the putative VP2 genes of BuV1, BuV2, BuV3 and TuV and generate virus-
like particles (VLPs) to be used in IgG EIA assays
3. To determine the BuV1-3 and TuV IgG seroprevalence in Finland, and assess the
potential cross-reactivity of these closely related viruses
In 2016, a third putative human protoparvovirus, CuV, was discovered. Besides in feces,
CuV DNA was detected in human skin biopsies, and this prompted the final studies of this
thesis
4. To clone the putative VP2 gene of CuV, generate VLPs, and add CuV to the
protoparvovirus IgG EIA panel
5. To determine the BuV1-3, TuV and CuV IgG seroprevalence worldwide
6. To assess the CuV IgG cross-reactivity with BuV1-3 and TuV
7. To set up qPCR methods for TuV and CuV DNA detection
8. To search for BuV, TuV and CuV DNA in skin biopsy samples from cutaneous T-cell
lymphoma (CTCL) and transplant patients and from healthy adults in Finland as well
as determine the IgG seroprevalence of all three viruses in these patient cohorts
Materials and methods
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3 MATERIALS AND METHODS
3.1 MATERIALS
3.1.1 STUDY COHORTS AND CLINICAL SAMPLES
Cohort 1, fecal samples from GE patients in Finland (I)
The GE cohort consisted of fecal samples from 629 gastroenteritis patients of all ages
(median 51.5 years, range 0–99) in Finland. The samples were obtained retrospectively
from routine diagnostics for bacterial (n=243) and viral (n=386) gastroenteritis-inducing
pathogens (HUSLAB, Helsinki University Hospital, Helsinki, Finland). The samples were
sent to HUSLAB from diverse locations within Finland and were collected either during
October 2012–March 2013 (bacterial samples) or in April–May 2013 (viral samples).
Cohort 2, fecal, nasal swab and serum samples from children in Finland (II)
The Tampere pediatric cohort consisted of 955 patients with symptoms of acute
gastroenteritis (AGE, n = 172), acute respiratory tract infection (ARTI, n = 545) or both
(n = 238). The recruited children (median 14 months, range 6 days – 15.6 years) were
either visiting an outpatient clinic (n=137, 14.3%) or were admitted to a hospital ward
(n=818, 85.7%) between September 2009 and August 2011 in Tampere, Finland. Fecal
and nasal swab samples were obtained from all patients and serum samples from 228 of
whom blood sampling was medically indicated.
Cohort 3, serum or plasma samples from healthy adults in Finland (II)
The student/staff cohort consisted of serum or plasma samples from 180 healthy adults
(median age 30 years, range 19–65) collected between 2007 and 2013 in Helsinki,
Finland. All 84 medical students from the University of Helsinki and 79/96 staff members
from the Helsinki University Hospital or from the Faculty of Medicine, University of
Helsinki, were of Finnish descent, the remaining 17 staff members were originally from
Asia (12), the Americas (1) or other European countries (4). Follow-up samples from BuV
IgG-positive individuals were obtained (frozen-stored) from our archive or collected from
participants.
Cohort 4, serum samples from veterinarians in Finland (III)
The veterinary cohort consisted of serum samples from 324 healthy adults (median age
40.2 years, range 19–79) collected from participants at the national Annual Veterinary
Congress in 2009 in Helsinki, Finland. The cohort consisted of veterinarians (82%),
veterinary students, and veterinary nurses, and most (92%) completed an electronic
questionnaire of background information.
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Cohort 5, serum samples from the United States (III)
The USA cohort consisted of serum samples from 84 healthy blood donors (median age
41.3 years, range 18–72) obtained from the Blood Systems Research Institute (San
Francisco, CA, USA). The samples were collected during April 2009 in 2 locations:
Arizona (n = 40) and Mississippi (n = 44).
Cohort 6, serum samples from Iraq (III)
The Iraq cohort consisted of serum samples from 99 healthy adults (median age 39.7
years, range 18–60) collected in November-December 2013 in Nasiriyah, Dhi Qar, in
southern Iraq.
Cohort 7, serum samples from Iran (III)
The Iran cohort consisted of serum samples from 107 healthy adults (median age 42.2
years, range 18–77) obtained from the Hamadan Blood Transfusion Organization,
Hamadan, Iran. The samples were collected during 2015-2016.
Cohort 8, serum samples from Kenya (III)
The Kenya cohort consisted of serum samples from 107 children (median age 6.9 years,
range 0.5-17.8) and 119 adults (median age 43.3 years, range 18–88) who had a febrile
illness of unknown cause and had visited health clinics in Wundanyi, Mwatate, or Voi in
Taita Taveta County in southern Kenya. All patients completed a questionnaire to provide
information of their backgrounds and current symptoms.
Cohort 9, tissue and serum samples from CTCL patients (IV)
The CTCL cohort consisted 25 patients (median age 64 years, range 32–89 years), of
whom 23 had mycosis fungoides and 2 leukemic Sezary syndrome. A FFPE skin biopsy
from CTCL lesion site was available from all. Additional FFPE tissue biopsies were
obtained from the pathology archives from 2 patients with CuV DNA in the original CTCL
biopsy: 2 prostate samples were available from one and 12 samples from the other,
including prostate, lymph node, melanoma, CTCL and other skin samples (Table 2 in
Study IV). Serum samples were available of a separate cohort of 42 CTCL patients,
including 3 whose skin biopsies were analyzed.
Cohort 10, tissue and serum samples from transplant patients (IV)
The transplant cohort consisted of 136 immunosuppressed solid-organ transplant
patients (median age 62 years, range 22–83 years, data not available from 5 patients),
who had received an organ transplant more than 5 years ago (median 10 years, range 5–
26 years). Most of the patients (131/136) received liver transplants, 4 received kidney, and
1 heart transplant. A fresh skin biopsy was taken from all: healthy skin biopsies were
available from 133 patients and suspected malignant or premalignant skin biopsies from
19 patients (19 carcinoma, 1 melanoma, 4 actinic keratosis; 1–4 biopsies per patient). A
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corresponding serum sample was available from 123 patients, and additional 1–3 serum
samples from the CuV, BuV, or TuV sero- or genopositive patients were obtained at
various time points before the skin biopsy. Overall, serum samples were available from
124 patients.
Cohort 11, tissue and serum samples from healthy adults (IV)
The healthy adult control cohort consisted of 98 immunocompetent adults (median age
48 years, range 18–67 years). A skin biopsy (1-2 per person, 159 in total) were obtained
from epicutaneous test areas for allergens or irritants. None had known skin
malignancies, although 15 adults had mild skin conditions such as atopic dermatitis. A
corresponding serum sample was available from 78 patients.
3.1.2 ETHICAL ASPECTS
All studies were conducted in accordance with the relevant guidelines and regulations. A
written informed consent was obtained from participants or from the guardian of the
child with cohorts 2-4, 6 and 8-11. The Ethics Committee of the Hospital District of
Helsinki and Uusimaa approved the studies using cohorts 1, 3, 4 and 9-11, and the Ethics
Committee of Pirkanmaa Hospital District the study using cohort 2. The National
Supervisory Authority for Welfare and Health (Valvira) approved studies using cohorts
9-11. Ethics Committees of Medical Sciences at Basrah University and the Al-Hussein
Teaching Hospital approved the use of cohort 6, and the Kenyatta National Hospital–
University of Nairobi Ethics and Research Committee the use of cohort 8. Informed
consent was waived for the deidentified blood donor samples in cohort 7, and the study
was approved by the Ethics Committee of Hamadan University of Medical Sciences,
Hamadan, Iran. Under US human and health service regulations, the study of preexisting,
deidentified samples is not classified as human subject research, and therefore a separate
approval for the use on cohort 5 was not applied.
3.1.3 PLASMIDS
For setting up the qPCR and later to serve as a positive control and in creating the
standard curve for quantification, a 3.5kb piece of the BuV1 genome was cloned from the
original BuV1 DNA-positive fecal supernatant (BF.7) with primers “BuV1-2 NS fwd KpnI”
and “BuV1 VP mid rev ApaI” (Table 2). The amplicon was cloned into pSTBlue vector with
KpnI and ApaI restriction sites.
For qPCR set up and optimization, a 830-nt piece of the BuV2 genome was cloned
from the original BuV2 DNA-positive fecal supernatant (BF.39) with primers “BuV1-2 NS
fwd KpnI” and “BuV rev” (Table 2).
For VLP expression, the putative VP2 genes of BuV1, BuV2, BuV3, TuV and CuV were
amplified from the original virus DNA-positive fecal supernatants34–36,129 with primers
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listed in Table 2. The obtained gene was cloned into the Bac-to-Bac system donor vector
pFastBacDual (Invitrogen) at the BamHI and SalI restriction sites under the strong
Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) polyhedrin
promoter. In addition, the VP2 genes of TuV and CuV were blunt cloned into pSTBlue
(Novagen/Merck) to serve as positive controls and for the qPCR set up.
All cloned sequences were confirmed by sequencing.
3.1.4 CELL LINES
Chemically competent cells of Escherichia coli -strains DH5α (New England Biolabs) or
E. cloni 10G (Lucigen) were used for routine cloning.
Escherichia coli -strain DH10Bac™ (Bac-to-Bac Baculovirus Expression System,
Invitrogen), carrying the AcMNPV parent bacmid and a recombination helper vector, was
used for creating recombinant baculoviruses carrying the VP2 genes of BuV1, BuV2,
BuV3, TuV and CuV.
Spodoptera frugiperda (Sf9) insect cells were used in creating the recombinant
baculoviruses, and Trichoplusia ni (HighFive) insect cells were used for VLP expression.
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3.2 METHODS
3.2.1 QUALITATIVE PCR
Qualitative PCR was used for two purposes in this thesis: i) to clone the VP2 gene or other
regions from the BuV1-, BuV2-, BuV3-, TuV- and CuV-positive patient samples to serve
as controls in qPCR as well as to be used in creating the recombinant baculoviruses for
VLP expression (Studies I-IV), and ii) to verify the positive qPCR results and to find out
the genotype or strain of the virus in the sample (Studies I and IV). These PCRs were
carried out with Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific) with
HF or GC buffer according to the manufacturer’s specific instructions for Phusion DNA
polymerase.
In study I, the BuV qPCR-positive samples were re-amplified either with BuV1 and 2
VP2 primers or with primers BuV1-2 NS fwd KpnI and BuV NS 1kb rev (Table 2).
In study IV, the CuV qPCR-positive tissue samples were re-amplified with CuV 583
fwd and CuV rev or with CuV 230 fwd and CuV rev (Table 2).
3.2.2 QUANTITATIVE PCR
During all qPCR experiments as well as qualitative PCR experiments from patient
samples, strict precautions were taken to avoid contamination. Separate rooms were used
for preparing the master mixes, handling and extracting DNA from sample material, and
preparing the plasmid controls and pipetting the plasmid templates. Aerosol resistant
filter tips were used throughout and all runs included H2O as negative template control.
3.2.2.1 Primer and probe design for qPCR (I,IV)
To design primers and probes for quantitative PCR for BuV, TuV and CuV, all respective
sequences available in GenBank were aligned with Clustal W or Clustal Omega, available
at the European Bioinformatics Institute webpage (https://www.ebi.ac.uk/services). To
obtain sequences for BuV singleplex design, GenBank was accessed 1st Oct 2012, and for
TuV and CuV singleplex as well as multiplex, GenBank was accessed 1st Jun 2016.
The conserved and variable regions between the viruses were manually searched for
with BioEdit160 and potential primer and probe sequences were analyzed in silico with
NetPrimer software (PREMIER Biosoft) and Amplify4 software. The Basic Local
Alignment Search Tool (BLAST, The National Center for Biotechnology) was used to see
any undesired matching to human or other sequences.
For BuV, the qPCR amplicon was designed to the NS gene region, which is nearly
identical between the different BuV types. For TuV and CuV, the qPCR amplicon was
designed to the VP2 region of the virus (see also Fig. 17).
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3.2.2.2 BuV qPCR (I)
A ten-fold dilution series of BuV1 plasmid containing a 3.5-kb piece of the BuV1 genome,
ranging from the NS to VP region, was used in the qPCR set up and as a quantification
standard in the final assay. During set up, the sensitivity and specificity of the assay were
tested also with the BuV2 plasmid (containing an 830-nt piece of the BuV2 NS gene) as
well as with i) 500 ng human DNA/reaction (HEK 293 cell line), ii) DNA extracted from
human fecal samples spiked with 500 copies of BuV1 plasmid, and iii) high copy number
plasmids of other human parvoviruses (B19V, HBoV1 and PARV4).
The final 25-μl reactions consisted of 1x Maxima Probe Master Mix (Thermo Fisher
Scientific) with 30 nM ROX reference dye, 0.5 μM of both BuV primers, 0.2 μM of BuV
NS1 probe, and 5 μl template. The BuV qPCR was set up with the Stratagene Mx3005P
machine (Stratagene) with the following program: initial denaturation of 10 min at 95°C
followed by 45 cycles of 15 s at 95°C and 1 min at 60°C. Of note, later on the protocol was
tested and used also with the AriaMx Real-Time PCR system (Agilent Technologies).
Primers and the probe are listed in Table 2.
3.2.2.3 TuV and CuV singleplex and BuV-TuV-CuV multiplex qPCR (IV)
A ten-fold dilution series of TuV and CuV plasmids containing the VP2 genes of the
respective virus were used to set up qPCRs and as a quantification standard in the final
assay. During set up, sensitivity and specificity of the assay were tested as singleplex and
multiplex with plasmids, with and without 450ng human DNA/reaction (HEK 293, HeLa,
hFSF, HepG2 or A549 cell line), and high copy number plasmids of other human parvo-
or polyomaviruses (B19V, HBoV1-4, and PARV4 and a mix of 13 human polyomaviruses).
For TuV and CuV qPCRs, the reaction set up was similar to that of BuV qPCR, except
that ROX was excluded from the master mix due the use of this channel for measuring
TxRed fluorescence of the TuV probe (Table 2). In addition, doubled concentrations of
the degenerate CuV fwd primer and CuV probe were used.
The final multiplex BuV-TuV-CuV-qPCR reaction consisted of 1x Maxima Probe
Master Mix (without ROX), 0.5 μM of each primer (1 μM for CuV fwd), 0.2 μM of each
probe (0.4 μM for CuV), 5 μl template, and H2O to a final volume of 25 μl. All primers and
probes are listed in Table 2.
The TuV and CuV singleplex and the BuV-TuV-CuV multiplex assays were set up with
the AriaMx Real-Time PCR system with the following program: 10 min at 95°C followed
by 45 cycles of 15 s at 95°C and 1 min at 62°C. The temperature in the combined annealing
and extension step was increased from 60°C to 62°C to ensure the specificity of the assay.
3.2.3 DNA EXTRACTION (I-IV)
All DNA extractions were made according to the manufacturer’s instructions unless
otherwise indicated.
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With cohort 1, the DNA was extracted either from 900 μl of 10% fecal suspension with
the NucliSens EasyMag nucleic acid extraction protocol (bioMerieux) using an automated
Tecan pipetting robot system (Tecan), or from 200 μl of a 10% fecal suspension with the
MagnaPure LC Total nucleic acid isolation kit (Roche Applied Sciences).
With cohort 2, the DNA was extracted from 140 ul 10% fecal suspension and from
nasal swabs suspended and mixed in UTM-RT Mini tubes (Copan) using the QIAamp
Viral RNA Mini Kit (Qiagen)127.
With cohorts 9, 10 and 11, DNA from freshly frozen tissue samples (4-5 mm in
diameter) was extracted with the QIAamp DNA Mini Kit or AllPrep DNA/RNA/miRNA
Universal Kit (Qiagen). DNA from FFPE tissue samples (1–20 × 10 μm sections,
depending on the availability and the amount of tissue in the blocks) was extracted with
QIAamp DNA FFPE Tissue Kit (Qiagen) with the following modifications:  i) tissue
sections were deparaffinized twice with xylene (Sigma-Aldrich), ii) the tissues were lysed
by incubating overnight in 180 μl ATL buffer and 20 μl proteinase K at 56?C, and iii) DNA
was eluted twice, first round with 40 μl and second round with 20 μl ATE elution buffer.
DNA from serum (200 μl) was extracted with the QIAamp DNA Blood Mini Kit (Qiagen).
3.2.4 VIRUS-LIKE PARTICLE PRODUCTION (II-IV)
The VP2-pFastBacDual plasmids were transformed into the E. coli host strain,
DH10Bac™, containing a parent bacmid and helper vector (Bac-to-Bac Baculovirus
Expression System, Invitrogen). By using the site-specific transposition properties of the
Tn7 transposon in the pFastBacDual vector expression cassette, the entire cassette was
transposed site-specifically into the bacmid.
The recombinant bacmid DNA was extracted with alkaline lysis, and the bacmid DNA
was transfected into Spodoptera Frugiperda (Sf9) cells with Cellfectin transfection
reagent (Invitrogen) to generate a recombinant baculovirus. The obtained baculovirus
stock was amplified in Trichoplusia ni (HighFive) insect cells three times according to the
manufacturer’s instructions.
For VLP expression, HighFive insect cells were infected with baculovirus (P3 virus
stock) and after 5 days of incubation in +27°C, the cells were collected by centrifugation
at 4300rpm for 5 min. The cells were re-suspended to 20 mM Tris-HCl, containing
Complete-EDTA-free protease inhibitor cocktail (Roche Applied Sciences) and frozen at
-20°C.
To free the VLPs from the insect cells, the cell suspension was incubated with 0.5%
deoxycholate (Sigma-Aldrich) at +37°C for 30 min with 600 rpm shaking. The treated
cells were cooled down on ice and sonicated 8 times with 10 sec sonication/10 sec interval
–scheme using 50% amplitude in the sonication phase. After centrifugation of the lysate
at 16100 g for 30 min at +4°C, the supernatant was collected, and the sonication
procedure was repeated for the remaining pellet. The supernatants from the two
sonication rounds were loaded onto a CsCl double cushion with densities of 1.52 g/cm3
and 1.22 g/cm3 in TE buffer (10 mM Tris-HCl (pH 7.8), 1 mM EDTA). Ultracentrifugation
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was performed at 65 000 g for 4 h or overnight at 10°C. Fractions were collected and those
showing pure VP2 bands on SDS-PAGE were dialyzed 3 times against PBS. The purified
VLPs were viewed under electron microscopy.
3.2.5 SEROLOGICAL ANALYSIS (II-IV)
All IgG EIAs were done with biotinylated antigens. The purified VLPs as well as the
sonicated HighFive insect cell lysate serving as control antigen were biotinylated with EZ-
Link Sulfo-NHS-LC-Biotin kit (Thermo Fischer Scientific) according to manufacturer’s
instructions.
Different plastics and buffers as well as various reagent concentrations were tested
during set up.
3.2.5.1 IgG EIA
BuV1-3-TuV-IgG EIA was set up and used as a panel in which each sample was analyzed
for each of the virus antigens and the insect cell control antigen in adjacent wells (Study
II). The antigens also controlled each other regarding the possible false positive reactivity
towards the plastics or other reagents. The CuV antigen was added to this panel in Study
III, and the entire panel was used also in Study IV.
Briefly, the final IgG EIA assay was the following: streptavidin-coated plates
(Kaivogen) were incubated with 80 ng of biotinylated antigen per well. After post-coating
with the Diluent (Labsystems diagnostics) 3 x 10 min, serum samples diluted 1:200 in
Red buffer (Kaivogen) were applied to wells and incubated for 1 hour in room temperature
with 400 rpm shaking. Wells were washed 4 x with PBST and horseradish-peroxidase-
conjugated antihuman IgG (DAKO) was applied and incubated for 1 hour in room
temperature with 400 rpm shaking. After the final washes of 4 x PBST, the bound IgG
was detected with 3-3’,5-5’-tetramethylbenzidine (TMB, Dako in II and III, Sigma-Aldrich
in IV). The reaction was stopped with 0.5 M H2SO4 and the ODs were measured with
Multiscan EX (Thermo Fisher Scientific) at 450 nm wavelength.
To interpret the sample as IgG positive or negative, no classical cut-off was defined,
i.e. using the results and standard deviations from known negative samples. Instead, all
samples showing of OD≥0.1 were confirmed with competition EIA (see next section), and
the final positive IgG result was always based on competition assay result. The OD≥0.1 –
value was decided from the information of the early experiments with BuV1 and BuV2
IgG EIA: samples showing OD<0.1 were not reliably repeated in the competition assay
and such values have not been considered positive in any other parvoviral IgG EIA in our
laboratory before (Lea Hedman, personal communication).
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3.2.5.2 IgG EIA competition assay
To study possible cross-reaction and to distinguish those from true reactivity, as well as
confirming the IgG-positive reactions for these novel viruses, a competition assay was
used as previously described for human bocaviruses103,105. For all samples showing
OD≥0.1 for any virus antigen, the EIA was repeated with homologous and heterologous
blocking. The IgG EIA protocol for competition assay was otherwise identical to the
normal IgG EIA, but the serum sample was incubated with the viral VP2-VLPs 20 μg/ml
or HighFive insect cell lysate 0.5 mg/ml for 1.5 hours at +4°C prior to adding the sample
to the well.
Initially all samples showing reactivity were blocked separately with each of the virus
antigens as well as with the insect cell lysate (Study II); later on, only the homologous
antigen, the antigen of the phylogenetically closest virus and the antigen of one other
protoparvovirus were used in the blocking (Studies III and IV). For example, a sample
showing BuV1 reactivity was blocked with BuV1, BuV3 (the closest virus), and either with
BuV2 or CuV. In case of unclear results, the blocking was repeated, and other antigens
were included to the blocking if needed. All TuV IgG reactivities in Studies III and IV,
were tested and blocked with TuV antigens from two different batches as well as at least
with two BuV antigens and insect cells. Of note, the routine blocking with insect cells was
discontinued in Studies III and IV and used only occasionally since the VLP purity was
increased and false positive reactions due to insect cells became rare.
In general, the competition assay result was interpreted as positive, when homologous
blocking removed all reactivity, and no or only little heterologous blocking occurred.
For BuV1, BuV3 and TuV, the competition assay result interpretation criteria stayed
the same in all studies as described in Study II (the first serological article): “The overall
BuV-IgG result after competition was considered positive when no heterologous
blocking occurred and the residual OD fell upon homologous blocking (i) below OD 0.2,
when the non-blocked OD was > 0.5; (ii) below OD 0.15, when the non-blocked OD was
0.3–0.5; and (iii) below 50% of the non-blocked OD, when the non-blocked ODs were
low, 0.1–0.3”.
After including CuV to the IgG EIA panel, the competition assay result interpretation
criteria needed to be updated for BuV2 and CuV due to cross-reactions. A sample was
considered CuV or BuV2 IgG positive when homologous antigen blocked the IgG
reactivity completely, the heterologous (BuV2 or CuV) only partially, and more distant
BuV1 or BuV3 antigen did not block at all.
3.2.6 STATISTICAL ANALYSIS
Statistical analysis was performed either in the OpenEpi software
(https://www.OpenEpi.com) with test statistics (mid p-exact value) and 2 x 2 tables
(study III), or with R, version 3.4.3 (R Development Core Team) for Mann-Whitney U,
and Pearson’s χ2 (study IV). A 2-tailed p value <0.05 was considered statistically
significant.
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4 RESULTS AND DISCUSSION
4.1 BUV DNA DETECTION IN FINLAND (I, II)
Introduction. In 2012 Phan and co-workers described a new parvovirus, BuV, in a fecal
sample of a diarrheic child in Burkina Faso, Africa. In the same study, three more samples
from Burkina Faso as well as one from Tunisia were shown by PCR to harbor the DNA of
this new virus.
To study the epidemiology and occurrence of BuV in Finland, a sensitive real-time
qPCR was designed for detecting and quantifying the viral DNA. In the first study, fecal
samples from a cohort of GE patients (n=629) of all ages in Finland were analyzed for
BuV DNA, and in the following study, fecal and nasal swab samples from children (n=955)
with AGE, ARTI or both symptoms were analyzed to further study the occurrence of this
virus.
BuV qPCR design and validation. The analysis of the alignment of four BuV
sequences available in GenBank at the time showed conserved areas in the NS region.
After manual analysis and in silico evaluation, a hydrolysis probe-based qPCR with a 126-
nt amplicon was designed. Within the primer areas, all four BuV sequences were identical,
and within the probe area, a single nucleotide difference between BuV1 and BuV2 types
was covered with a degenerative nucleotide. The commonly used FAM was selected as the
fluorescent dye to the probe, and Black Hole Quencher-1 (BHQ1), a non-fluorescent
chromophore, was used for quenching the fluorescent signal. The NetPrimer and
Amplify4 in silico analyses revealed no significant dimers (primer-primer or primer-
probe) or hairpin formation.
The analytical sensitivity of the BuV qPCR was 5-10 copies per reaction with both
BuV1 and BuV2 plasmids (see 1.4.3 plasmids), and 500 ng of human DNA did not affect
the BuV quantification or cause false positives. No false amplification was seen with high
copy-number plasmids of the other human parvoviruses, B19V, PARV4 and HBoV1.
At the time when Study I was published, a third genotype of BuV, BuV3, was
described129. Consequently, a question was raised, whether the developed primers and
probe matched the novel BuV3 sequences. In silico analysis demonstrated single
nucleotide mismatches between each of the oligos and the BuV3 sequences, however,
none of the BuV3 sequences harbored two or all three of the observed mismatches, and
therefore, these mismatches were not considered to cause fundamental detection or
quantification problems. Of note, later on we analyzed BuV3 DNA-positive fecal samples
with the qPCR assay and were able to detect and quantify the BuV3 DNA in the sample
even from low copy-number samples (unpublished data).
BuV DNA prevalence among GE patients in Finland (Study I). Seven fecal
samples harbored BuV DNA (7/629, 1.1%), of which four were from the bacterial cohort
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(4/243, 1.6%) and three from the viral cohort (3/386, 0.8%). All positive samples
contained low viral DNA quantities ranging from 1.9E+03 to 3.2E+04 copies per ml of
fecal suspension. Despite low copy numbers, the entire 1.7 kb VP2 was amplified from five
samples and partial NS (~1 kb) from one, and sequencing showed that all amplicons were
most similar to BuV genotype 1 (Technical Appendix Fig. in Study I). One sample was
positive only by the short BuV qPCR (repeatedly), but no longer sequence could be
obtained. This was most likely due to the very low viral quantity in the sample: 1.9E+03
per ml of fecal suspension, correlating to 9.6E+00 copies per reaction, which was the
lowest quantity detected among the seven BuV DNA-positive samples.
In contrast to the other publications at the time, all samples from children were BuV-
DNA negative, and the seven samples harboring BuV DNA were from adults (median age
53 y, range 21–89 y). Overall, the analyzed samples were obtained from patients of all
ages (median 51.5 y, range 0-99 y), however, the majority of the samples were from adults.
Altogether there were only 81 samples from children below the age of 13 years and very
few from teenagers, and the smaller sample number may have been one reason why no
BuV DNA was detected among children. The age distribution of the patients is depicted
in Figure 13 (unpublished data).
Figure 13.   Age distribution of the gastroenteritis patients (n=629) in Finland (Study I). The orange  
columns represent the bacteriological cohort (n=243) and the blue columns the 
virological cohort (n=386). The numbers on top of the columns indicate the numbers of 
BuV DNA-positive samples in each age group and sample cohort. *, both samples 
were from the same patient
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Two of the three positive samples in the viral cohort came from the same patient, an
89-year-old lady living in western Finland, and the samples were taken 4 days apart. The
second sample showed a higher BuV copy number than the first, 3.2E+04 vs. 3.6E+03,
respectively. The higher viral load in the latter sample as well as the presence of virus in
two samples taken four days apart could imply that the virus was not derived from food
sources. However, as norovirus was detected in the second sample (the first sample being
norovirus negative), it might be that the GE symptoms were caused by norovirus instead
of BuV. The other five BuV DNA-positive patients were negative for the GE pathogens
tested in routine diagnostics.
BuV DNA prevalence in fecal and nasal swab samples of children in Finland
(Study II). To study the BuV occurrence among Finnish children as well as in other
sample types, fecal and nasal swab samples from a large pediatric cohort were analyzed.
Of the 955 children, three (0.3%) had BuV DNA in the feces and one (0.1%) in the nasal
swab sample. The BuV DNA quantity was very low in all four samples ranging from
8.5E+02 to 1.6E+03 copies per ml fecal suspension and 4.6E+03 copies per ml nasal swab
medium. The children with BuV DNA in their fecal samples were between 10 months and
4.5 years of age, and the swab-positive child was 20 months of age. All four patients
suffered from acute gastroenteritis, and a known GE pathogen was detected in every case.
Two children had norovirus, one had rotavirus and HBoV2, and the child with BuV DNA
in the nasal swab was positive for norovirus in the feces as well as had a serologically
confirmed acute HBoV2 infection. However, the fecal sample of the child remained BuV-
DNA negative, and no BuV-IgG antibodies were detected in his serum.
These results showed that BuV can also be found in Finnish children. Although BuV
was detected only in children with acute GE symptoms, and all tested 545 non-diarrheic
children were BuV-DNA negative, a known GE pathogen was detected in each of the BuV
DNA-positive cases and was most likely the etiological agent of the GE symptoms in these
children. In addition, the study did not include healthy children without symptoms of an
infection, and such individuals with identical sampling times should be analyzed to give
a better understanding of the role of BuV in gastroenteritis and other diseases.
Summary of BuV DNA studies. These two studies showed that BuV DNA can be
detected in Finland both in adults and in children, although with low prevalence and low
quantities, which is in line with the other publications (Table 3). Study I was among the
first articles reporting BuV DNA outside Africa as well as the first one reporting BuV in
Europe and in adults.
Currently, the presence of BuV DNA in human fecal samples has been reported in 17
studies around the world (including Studies I and II): in nine the analyses were done with
PCR (nested, quantitative or real-time) and in eight with NGS. Of note, the results from
one NGS study detecting BuV3 reads in Ethiopia has been published in two separate
articles161,162, although here and in Table 3 they are counted as one study.
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In the larger, PCR-based studies including >200 study subjects (n=8, Table 3), BuV
DNA has been detected in 0.3-1.7% of the fecal samples. A higher BuV-DNA prevalence
has been observed only in the original BuV article reporting BuV DNA by PCR in 4.1%
(4/98) of the children in Burkina Faso34, and in two NGS articles reporting BuV reads in
6.7% (4/60) of healthy Amerindian children in isolated Amazonian villages in
Venezuela135 and in 8.3% (1/12) of control children in an IBD study in the USA137.
Interestingly, even with the growing number of publications, the DNA of BuV2 has still
not been reported in any study since the original discovery.
The BuV DNA detected in the nasal swab in Study II is to date the only case describing
BuV DNA in another human sample type than feces. The studies have, however, either
focused on analyzing fecal samples and environmental water or reporting reads of BuV as
one of the NGS findings in a large virome analysis of fecal samples. Overall, there are only
three publications besides Study II reporting BuV PCR analyses of other human sample
types than feces: a study with cerebrospinal fluid (CSF) samples163, a study with biopsies
from head and neck cancers164 and Study IV (see also Chapter 4.4). In all three studies no
BuV DNA was detected.
In Studies I and II, all samples harboring BuV DNA were collected during
winter/spring months. The samples in the children’s cohort (Cohort 2) were collected
year-round, whereas with Cohort 1, the samples were collected between October and May.
It is well known that many other viruses cause epidemics during certain time of the year,
and sufficient sampling, including the sampling time span, should be taken into
consideration when planning the forthcoming studies. Currently, most BuV studies
including GE patients and controls, the samples in the control group have not been
collected at the same time period than the actual cases, although the ages of the cases and
controls might be well matched.
Regarding the possible association of BuV and gastroenteritis, no strong evidence has
been obtained although most of the BuV DNA-positive individuals have had
gastroenteritis. Recently BuV DNA has been detected also in non-diarrheal individuals135–
137,165, many BuV DNA-positive individuals have further had a known GE pathogen in the
feces and all reported viral loads have been low. Regardless of GE, BuV could cause
symptoms of other types, and the detected BuV DNA in feces could originate from
previous or current infections unrelated with GE or prolonged virus secretion, which is a
common phenomenon with HBoVs101,128,166.
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4.2 FIRST SEROLOGICAL STUDY OF BUV AND TUV (II)
Introduction. The mere presence of viral DNA in a secretion sample does not
necessarily mean that the virus has infected the individual. Viral DNA present in a fecal
sample can be derived from food sources and in nasal swab from inhaled air. Especially
when the viral quantity in a sample is low, it is difficult to evaluate whether the detected
DNA is coming from an infection or from an outside source. Viral antibodies provide an
excellent marker of a true infection as well as a good record of past infections.
It has been shown for B19V, HBoV1-4 and PARV4, that the major capsid protein VP2
(or VP3) alone can form the capsid, and such VLPs can be used as an antigen in serological
assays14,176–179. Therefore, VP2 proteins of BuV1, BuV2, BuV3 and TuV were expressed in
insect cell cultures, purified with ultracentrifugation, and used as antigens in an IgG-EIA
assay. Using the novel method, BuV1-3 and TuV IgG antibodies were analyzed among
adults (n=180) and children (n=228) in Finland to evaluate the IgG seroprevalence of
these viruses.
BuV1-3 and TuV VP2 amplification and cloning. The VP2 genes of all four viruses
were successfully amplified from the patient samples and cloned to pFastBacDual donor
vector with BamHI and SalI restriction sites.
The BuV1-VP2 gene of 1710 bps was amplified from sample BF.7 (GenBank
#JX027295). The obtained sequence had two nucleotide mismatches compared to
JX027295, of which one was synonymous and the other caused an amino-acid change in
position 421 (threonine to isoleucine). The amplification and cloning were repeated,
nevertheless, the nucleotide change remained. As the same nucleotide was obtained in
two different amplification rounds indicates that the nucleotide might be truly present in
the virus, and the clone was used to create the recombinant baculovirus and BuV1-VP2
VLPs. The VP2 sequence was deposited to GenBank (#KX856937).
The BuV2-VP2 gene of 1710 bps was amplified from sample BF.39 (GenBank
#JX027297). The obtained sequence had a single nucleotide mismatch compared to
JX027297, which was synonymous, and thus the amplification was not repeated. The
clone was used to create the recombinant baculovirus and BuV2-VP2 VLPs, and the VP2
sequence was deposited to GenBank (#KX856938).
The BuV3-VP2 gene of 1719 bps was amplified from sample BTN-310 (GenBank
#AB847989), and the obtained sequence was identical to AB847989. The clone was used
to create the recombinant baculovirus and BuV3-VP2 VLPs, and the VP2 sequence was
deposited to GenBank (#KX856939).
The TuV-VP2 gene of 1698 bps was amplified from sample Tu491 (GenBank
#KJ495710), and the obtained sequence was identical to KJ495710. The clone was used
to create the recombinant baculovirus and TuV-VP2 VLPs, and the VP2 sequence was
deposited to GenBank (#KX856940).
Results and discussion
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Recombinant BuV1-3 and TuV VP2 protein expression and VLP purification.
HighFive insect cells were infected with the recombinant baculoviruses and the SDS-
PAGE analysis of the infected cells showed a band located between the 50 and 75-kDa
bands of the protein size marker. After purifying the putative VLPs with the CsCl
ultracentrifugation, the same band of ~64 kDa for BuVs and ~62 kDa for TuV was present
in SDS-PAGE (Fig. 1 in Study II). Electron microscopy of the purified VLPs showed
parvoviral-like capsids of ~25 nm in diameter (Fig. 14)
Figure 14. Electron microscopy pictures of purified BuV1, BuV2, BuV3 and TuV-VP2 VLPs.
Scale bar 100 nm.
BuV1-3 and TuV IgG EIA assay. An antigen concentration of 80 ng per well was
shown to be optimal for all four viruses, and all IgG EIAs could be carried out in the same
assay conditions facilitating the use of the four EIAs as a panel. In the IgG panel, a single
well per antigen was used for sample screening, and the antigens were controlling each
other for example regarding possible unspecific background caused by plastics or other
reagents. HighFive insect cell antigen (biotinylated cell lysate) was included to the panel
to monitor any possible cross-reactions from insect cell traces left in the purified VLPs.
BuV-IgG prevalence in adults. BuV IgG was detected in ten subjects (10/180, 5.6%)
of which four had BuV1 IgG, five BuV2 IgG and one had IgG towards all three BuV types.
Interestingly, although 90.7% of the subjects (163/180) were of Finnish descent, half of
the BuV IgG-positive subjects originated from India, the Middle East or China resulting
in a remarkable difference in BuV IgG seropositivity between Asian (5/12, 41.7%) and
native Finnish subjects (5/163, 3.1%). While the result was intriguing and could direct
further serological studies towards Asian and Middle Eastern countries, it did not reach
statistical significance due to the low number of samples.
Persons with Asian background had moved to Finland as adults and were 26 to 34
years of age during sampling time.  The other BuV IgG-positive persons were 22-26-year-
olds, except one that was 56 years old. Among the Finnish BuV IgG-positive subjects, all
showed low OD values, whereas the subjects with high ODs were from Asia. These
included three BuV1 IgG-positive persons from India and the triple positive person was
from the Middle East.
To study if the BuV IgG seropositivity is long-lived, similarly to other human
parvoviruses, follow-up samples were analyzed from five seropositive persons. The
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analysis showed that IgG could be detected for at least 6 years, and in all cases the
antibody titre reflected by the OD values remained stable throughout the follow-up period
(Table 2 in Study II and Table 4). Overall, these results show that BuV infections elicit
strong and long-lasting immune reactions similarly to those of B19V and HBoV1.
BuV-IgG prevalence in children. Of the 955 children with stool and nasal swab
samples that were analyzed by BuV qPCR, serum samples were available from 228
children. Seven (3.1%) harbored BuV IgG: one for BuV1, three for BuV2, two for BuV3
and one had both BuV1 and BuV2 IgG. The children with BuV1 and/or BuV2 IgG were 1-
to 5-year-olds, whereas the two children with BuV3 IgG were only 7 and 8 months of age,
and thus the low-level BuV3 IgG could be of maternal origin. In general, the maternal
antibodies are considered to disappear from the child by the age of six months, but
without knowing the serological status of the mother, the possibility should be kept in
mind.
From the three children with BuV DNA detected in the stool, no serum sample was
available, and for the child with BuV DNA in the nasal swab, the corresponding serum
sample was BuV-IgG negative. The lack of IgG in the latter child could indicate that either
the BuV DNA detected in the nasal swab was not from an infection or that the infection
was at a too early phase for IgG to have formed yet. Although this child was suffering from
many underlying health issues such as heart problems, asthma and operated cleft palate,
a serologically confirmed acute HBoV2 infection127 indicated that the child had a normally
functioning immune system, and a normal immune response towards (parvo)viral
infections.
The overall BuV seroprevalence among the Finnish children was the same as among
the native Finnish adults. Why the prevalence did not rise with age, is not known. Waning
of antibodies can have an effect, however, it was shown that the IgG stayed for at least 6
years without any change in the OD value (OD value reflects the antibody titre in a
sample) (Table 2 in Study II). As the circulation of these viruses in Finland seems to be
rare, a natural boosting of the antibody titre by repeated exposures to the virus does not
occur, thus the antibody level could eventually wane away. All samples with high OD were
from individuals who had moved to Finland as adults and most likely had been infected
before. It could be hypothesized that these individuals had been living in an environment
where these viruses circulate, and they acquired natural stimulation to the immunity and
maintenance of the specific antibodies.
BuV competition assay and cross-reactivity. Previously it has been shown for
HBoV1-4 that these closely related parvoviruses cross-react in serological assays, and the
results need to be verified by a competition assay105. The HBoVs differ 11-23% at the VP2
protein level105, and although the VP2 proteins of the three BuVs differ more (27-
35%)129,133, cross-reactions may occur. Thus, the competition assay was used to
distinguish between specific and false reactivity in the IgG EIA as well as study the
potential cross-reactivity of the viruses.
Results and discussion
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The competition-assay results suggested that BuV genotypes represent also serotypes.
When BuV IgG-positive samples were blocked with different antigens in separate wells,
only the homologous antigen was able to remove the reactivity while the heterologous
antigens did not (Table 4 and Table 3 in Study II). The same result was observed with all
three BuV types, with samples harboring IgG towards one, two or all three BuV types, and
with samples with high or low OD values: each IgG reactivity was blocked only with the
homologous antigen (Table 3 in Study II). In addition, the blocking characteristics were
identical in the follow-up samples taken up to 6 years apart (Table 4). The lack of cross-
reactivity and the presence of specific antibodies towards more than one BuV in a single
individual argues against the presence of original antigenic sin between the BuV types.
However, properly diagnosed consecutive infections of different BuV types are needed to
fully address this question.
Table 4. Examples of IgG competition-assay results from adults with follow-up samples. 
The samples were taken 6 months (case 2) and 6 years (cases 1 and 5) apart. In 
each sample only the homologous antigen blocked the reactivity, i.e. BuV1 blocked 
BuV1 etc. The numbers represent OD values from the IgG EIA and specific 
blocking is illustrated with bolded numbers. Further examples of competition-assay 
results are presented in Table 3 of Study II.
Subject Case 1 Case 2 Case 5
Sampling date 4.3.2010 18.2.2016 6.1.2011
19.7.
2011
19.10.
2009
17.2.
2016
Antigen in the
well BuV1 BuV2 BuV3 BuV1 BuV2 BuV3 BuV1 BuV1 BuV1 BuV1
Bl
oc
ki
ng
 a
nt
ig
en
None 2.588 2.761 2.896 2.683 2.419 2.675 3.095 3.855 0.223 0.249
BuV1 0.030 2.587 2.661 0.033 2.356 2.567 0.035 0.029 0.058 0.095
BuV2 2.579 0.038 2.722 2.487 0.032 2.614 3.063 3.285 0.217 0.256
BuV3 2.400 2.614 0.080 2.532 2.391 0.088 3.532 3.466 0.204 0.270
TuV 2.513 2.720 2.819 2.530 2.424 2.686 3.369 ND 0.196 0.252
H5 2.638 2.845 2.954 2.653 2.630 2.645 3.702 3.182 0.221 0.269
H5, HighFive insect cells; ND, not done
TuV-IgG prevalence in adults and children, and competition assay results. All
adults were TuV-IgG negative, while TuV IgG was detected in one 9-year-old child (1/228,
0.4%). Although the OD value was low (OD 0.31), five times more blocking antigen was
needed to remove the reactivity. However, as the other antigens did not clearly block the
reactivity, the sample was considered TuV IgG positive (Table 3 in Study II). Nevertheless,
it needs to be remembered that there are no positive controls for TuV IgG assay
development and therefore the functionality of the assay is not fully known. The IgG EIA
assays for other human parvoviruses using the same assay principles than the TuV IgG
EIA have been successful before, and therefore the TuV IgG EIA could be hypothesized to
function as well.
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Insect cell derived cross-reactivity. Despite that the viral antigens showed no cross-
reactivity, false positive reactions were occasionally demonstrated, mainly deriving from
insect cell traces. From 5 to 6% of the tested samples both in the adult’s (9/180) and
children’s (13/228) cohorts exhibited reactivity to HighFive insect cell control antigen.
Therefore, insect cell lysate was used in the competition assay as one of the blocking
antigens to further confirm the IgG results.
Of the viral antigens, the BuV2-VP2 VLPs were particularly prone to contain insect
cell impurities. Whether a lower expression of BuV2 VP2 in general, or other properties
of the capsid, was the main reason for the insect cell background remains to be elucidated.
Different variations of the VLP purification method were tested to increase the purity of
BuV2-VP2 VLPs, and ultracentrifugation of the VLPs twice was shown to be the best
option (data not shown).
In the competition assay the IgG reactivity was considered to be caused by insect cell
traces when blocking with the insect cell lysate removed the reactivity and the
homologous virus antigen did not or did less so. Of note, also the virus antigen used for
blocking contained insect traces as did the biotinylated antigen in the well, and therefore
was able to block some of the reactivity caused by the insect cells. An example of the insect
cell background and how the blocking assay worked in such cases is presented in Table 5.
Table 5. Example of insect cell derived false reactivity to BuV2. The competition-assay 
results from a sample from a healthy Finnish adult showing false reactivity to BuV2. 
The sample was interpreted as BuV2 IgG negative as the reactivity was not removed by 
BuV2, but with insect cells instead. The numbers represent OD values from the IgG 
EIA, and specific blocking is illustrated with a bolded number.
Antigen in the well BuV2
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none 0.159
BuV1 0.168
BuV2 0.168
H5 insect cells 0.052
         H5, HighFive insect cells
Results and discussion
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4.3 GLOBAL SEROPREVALENCE OF BUV, TUV AND
CUV (III)
Introduction. The results from Study II showed that IgG towards all three BuVs can be 
detected among children and adults, and the three BuVs seemed to be serotypes. The high 
BuV IgG prevalence detected among the Asian adults compared to the Finnish 
individuals, suggested that there might be countries and areas where BuVs are more 
prevalent. This inspired us to study populations from different countries and continents 
to find endemic areas for the three BuVs.
Besides the three BuVs and TuV, another human protoparvovirus, cutavirus (CuV), 
was discovered in 2016. Based on the phylogenetic analysis of NS1, CuV was classified as 
a close relative of BuV, although a different species. However, in the VP2, BuV2 was closer 
to CuV than it was to BuV1 and BuV3: the VP2 proteins of BuV2 and CuV showed 82%
similarity, whereas the VP2s of BuV1 and BuV3 were only 63-65% similar to that of CuV. 
Although the BuVs did not cross-react in our previous study, such reactions might occur 
between BuV2 and CuV.
We expressed and purified the CuV-VP2 VLPs and included CuV to the IgG-EIA panel 
and competition assay. With the IgG EIA panel, plasma or serum samples from altogether 
733 adults from Finland, the United States, Iran, Iraq and Kenya, as well as from 107 
children from Kenya, were analyzed to determine the BuV, TuV and CuV IgG prevalence 
in five countries located on four continents.
CuV VP2-VLPs and IgG EIA. The CuV VP2 gene of 1710 bps was amplified from 
sample Br337 (GenBank #KT868811). The obtained sequence had two nucleotide 
mismatches compared to KT868811, however, they were synonymous. The VP2 gene was 
cloned to the pFastBacDual donor vector with BamHI and SalI restriction sites, and the 
clone was used in creating the recombinant baculovirus and CuV-VP2 VLPs as described 
earlier for BuVs and TuV. The CuV VP2 sequence was deposited to GenBank 
(#MH127919).
SDS-PAGE analysis of the purified CuV-VP2-VLP yielded a band of ~64 kDa (Fig. 1 in 
Study III), and electron microscopy showed parvoviral-like capsids of ~25 nm in diameter 
(Fig. 15).
Figure 15. Electron microscopy picture of purified CuV-VP2 VLPs. The scale bar 100 nm.
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CuV-VP2 VLPs were biotinylated and used as antigens in the EIA. The same IgG EIA
protocol as used for BuVs and TuV was shown to work with CuV as well, and CuV was
thus included in the existing human protoparvovirus IgG EIA panel.
Global BuV-IgG seroprevalence in adults. The BuV-IgG prevalence varied greatly
between the countries: in Finland and in the USA, BuV IgG was detected in 2-4% of the
adults, whereas in Iran, Iraq and Kenya, 56-85% of the adults were seropositive (grey
columns in Fig. 16 and Table 2 in Study III). These results indicated that the Middle East
and Africa are endemic areas for BuV infections, and in contrast, in Finland and in the
USA BuV is not common. The result also confirmed our preliminary finding in Study II
that there are large variations in BuV-IgG prevalence between different geographical
regions.
The predominant BuV type was BuV1 in the Middle East, and BuV3 in Kenya and in
the USA (Fig. 16). Within the endemic areas, the IgG prevalence of the three genotypes
were more evenly distributed in Kenya than in the Middle East. In Kenya the predominant
BuV3 IgG was present in 65% of all BuV-IgG positives (56 BuV3 IgG positives among 86
BuV seropositives of any type), whereas in the Middle-East the predominant BuV1 IgG
was present in 92-95% of the BuV IgG positives (80 BuV1 IgG positives among the 86 BuV
seropositives in Iraq and 55 BuV1 IgG positives among the 60 BuV seropositives in Iran)
(Fig. 16).
Figure 16. IgG seroprevalence of BuV1, BuV2, BuV3, TuV and CuV in adults in five countries.
The “any BuV” bar indicates the persons harboring BuV IgG towards one or more BuV
types.
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BuV2 was the second most prevalent in IgG EIA in all endemic countries. This is an
interesting finding as BuV2 DNA has been detected only in a single child to date34. All
other BuV DNA findings have been of BuV1 or 3 worldwide when genotyping has been
possible. As BuV DNA has been searched for mostly in fecal samples, it could be that BuV2
is more likely present in a different sample type for example from the respiratory system
or from blood if the patient was viremic.
Individuals that harbored BuV antibodies towards more than one BuV type were
encountered most among the Iraqi and Kenyan adults: 30.3% (30/99) of Iraqis and 25.5%
(30/119) of Kenyans had antibodies against two BuV genotypes and 7% (7/99) and 5%
(6/119) against all three, respectively. In Iran, the double and triple IgG positive persons
were less common, 13.1% (14/107) and 1.9% (2/107), respectively. In Finland and in the
USA each BuV IgG positive individual had IgG of only one BuV type. Of note, in Finland
one veterinarian had both BuV2 and CuV IgG.
In contrast to Study II, some cross-reactions between the three BuVs were observed
in the samples from countries with high seroprevalence. The cross-reactions were mostly
seen in samples with high OD, and they were easily distinguished from true positivity with
the competition assay. Nevertheless, the low-level false reactions demonstrated that all
IgG reactivities should be verified with the competition assay for correct result
interpretation.
BuV-IgG prevalence among veterinarians in Finland. In Study III, all studied
adults from Finland were veterinarians (82%), veterinary students or veterinary nurses.
The BuV IgG prevalence was 1.9% (6/324), which was very similar to the prevalence
among Finnish adults in Study II (3.1%, 5/163). This suggests that BuV infections are not
increased by animal contacts, at least among Finnish veterinarians. In addition, no
specific animal contacts were observed among the BuV IgG-positive veterinarians
compared to the rest of the cohort.
Age related BuV-IgG prevalence. The BuV seroprevalence among children in Kenya
rose according to age: 6/50 (12.0%) of the <5-year-old children had antibodies towards
one or more BuV types compared to that of 16/57 (28.1%) in 5-17-year-old children, and
86/119 (72.3%) in adults (>18 y) (<5 y vs 5-17 y, P=0.043, <5 y vs >18 y, P<0.0001, 5-17
y vs >18 y, P<0.0001) (Table 6). The BuV genotype distribution pattern was similar in all
Table 6. BuV1, BuV2, BuV3, TuV and CuV IgG seroprevalence according to age in Kenya.
The “Any BuV” column presents individuals that harbor IgG towards one or multiple BuV
types. The numbers represent the number of positives (%).
n Any BuV BuV1 BuV2 BuV3 TuV CuV
<5 years 50 6 (12.0%) 0 (0.0%) 0 (0.0%) 6 (12.0%) 0 (0.0%) 2 (4.0%)
5-17 years 57 16 (28.1%) 3 (5.3%) 4 (7.0%) 14 (24.6%) 0 (0.0%) 0 (0.0%)
>18 years 119 86 (72.3%) 31 (26.1%) 43 (36.1%) 56 (47.1%) 0 (0.0%) 5 (4.2%)
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age groups. These results suggest that the age of acquisition of BuV differs from HBoV1.
but resembles more that of B19V.
The age-dependent increase of BuV seroprevalence prompted the analysis of the adult 
cohorts according to age. The cohorts were divided to under and over 40-year-olds, and 
in Iran a clear difference in BuV seroprevalence was observed: 39% (21/54) of the 18-40-
year-olds harbored BuV IgG compared to that of 74% (39/53) in 40-77-year-olds 
(P=0.0003) (Table 3 in Study III). Such a difference was not seen in Iraq (89% 18-40 y vs 
82% 40-60 y) or in Kenya (71% 18-40 y vs 72% 40-88 y). However, when the adult cohorts 
were divided into under and over 30-year-olds, in Kenya an age-dependent trend was 
noted (56% [14/35] vs 76% [70/92], P=0.0595), whereas in Iraq the trend was still absent. 
The differences seen between the under and over 40-year-olds in Iran could be caused by 
cultural or socioeconomic changes over time or by decreased BuV circulation in the area. 
In Finland and in the USA the low overall BuV seroprevalence caused any difference to be 
statistically insignificant.
Global TuV-IgG seroprevalence. TuV IgG was absent in all cohorts. As the TuV is 
phylogenetically closest to animal protoparvoviruses, it has been speculated whether TuV 
could actually be an animal virus, for example a rodent virus, instead of a human virus. 
The viral DNA originally detected in the child’s feces could have been derived from food 
or the environment. In general, parvoviruses are species-specific, i.e. they are causing 
infections only in a specific host or its close relatives and crossing the species line to 
another host is very rare. Here, 324 veterinarians from Finland were TuV IgG negative, 
and thus if TuV infects pets, livestock or fur animals in Finland, the virus did not jump 
into another host and infect the veterinarians treating the sick animals.
Global CuV-IgG seroprevalence. In contrast to the significant differences in global 
BuV seroprevalence, the CuV IgG prevalence was generally low in all studied populations 
(Fig. 16). The highest prevalence was among Iranians (5.6%, 6/107), Finnish 
veterinarians (4.9%, 16/324) and Kenyan adults (4.2%, 5/119). In the cohort of healthy 
blood donors from the USA CuV IgG was absent, and in Iraq only one person (1%, 1/99) 
harbored CuV IgG. Among the Kenyan children, two 3-year-old children had CuV IgG 
with high OD, while all the other children were CuV-IgG negative (age range 0.5-17 y).
Interestingly, in Iran all six individuals with CuV IgG were over 50 years of age, while 
in Kenya all five CuV IgG positives were under 40 years of age. In the veterinarian cohort 
in Finland, the CuV IgG-positive persons were between 29 and 66 years of age, and in 
Iraq the single CuV IgG-positive individual was 25 years of age. The different age 
distributions could be explained by rarity of CuV infections in general or by possible 
differences in the epidemiology of CuV. It could also be that CuV was introduced to Kenya 
only recently. In addition, the presence of serologically divergent CuV, that cannot be 
accurately detected by our IgG serology, is possible. More longitudinal serological as well 
as DNA studies are needed to confirm the variation and possible reason behind the CuV 
epidemiology. 
68
Results and discussion
CuV and BuV2 IgG cross-reactivity. CuV and BuV2 were clearly cross-reactive in the 
IgG EIA, and in nearly all samples showing reactivity towards one of the antigens, 
reactivity towards the other was observed as well. Only in samples with low OD the cross-
reaction was occasionally absent. Nevertheless, the competition assay was successfully 
used to distinguish true from false positivity: the true reactivity was blocked completely 
only with the homologous antigen but was only lowered by the other, whereas the false 
reactivity was completely removed by both (Table 7). The cross-reactions could be 
separated reliably in most of the cases, but the results from six unclear cases were 
excluded from the prevalence calculations. In addition, we encountered three individuals 
with IgG towards both CuV and BuV2, which suggested that the antibodies towards one 
virus does not prevent the formation of antibodies towards the other virus. Thus, it seems 
that the infection of BuV2 or CuV does not cross-protect from infection of the other, 
however, further studies are needed for more conclusive results.
Table 7. Competition assay results from three Kenyan patients showing BuV2 and CuV IgG
reactivities. The sample was considered positive, when only the homologous antigen
blocked the reactivity completely. For example, with patient 126, the CuV reactivity is
blocked completely only with CuV whereas the BuV2 reactivity is blocked with both BuV2
and CuV. The numbers represent OD values from the IgG EIA, and blocking is illustrated
with bolded numbers.
Patient no, age 462, 36 y 242, 20 y 126, 22 y
Result interpretation BuV2 and CuV IgG pos BuV2 IgG pos CuV IgG pos
 Antigen in the well BuV2 CuV BuV2 CuV BuV2 CuV
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none 2.566 1.898 1.194 0.475 1.715 2.501
BuV1 2.390 1.797 1.172 0.472 1.598 2.312
BuV2 0.081 0.770 0.035 0.046 0.036 1.484
CuV 1.582 0.107 0.510 0.044 0.031 0.028
y, year
BuV, TuV, and CuV IgG prevalence among HIV-positive individuals. The 
Kenyan cohorts included HIV-positive persons, 38/119 in the adult cohort and 9/107 in 
the child cohort. The BuV seroprevalence was very similar between the HIV-positive 
adults (median age 46 y, range 27–85 y) and HIV-negative adults (median age 38 y, range 
18–88 y): 79% (30/38) versus 69% (56/81) had BuV IgG, respectively (P=0.275). When 
the age ranges of the HIV-positive and -negative adults were matched, the 
seroprevalences were even more alike; 79% vs 75% (P=0.669), respectively (Table 8). 
Similarly, the CuV IgG prevalence did not vary between the HIV-positive and -negative 
adults: 2.6% (1/38) versus 3.4% (4/81) (no age matching, P=0.627), or 2.6% versus 3.3%
(2/60), (age matched cohorts, P=0.892). The HIV-positive and -negative children had 
also similar BuV and CuV IgG seroprevalences, however, the low number of HIV-
positive children restricted the statistical comparisons. All Kenyans were TuV IgG-
negative.
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These results suggested that the infection route of BuV and CuV differs from that of 
HIV in Kenya, and that HIV infection does not predispose the individual for BuV or CuV 
infection. With other human parvoviruses, PARV4 has been shown to be transmitted 
through blood-borne routes similar to HIV and HCV in Europe with the highest risk in 
intravenous drug users: the PARV4 IgG seroprevalence was 20-95% among risk groups 
compared to 0-4.7% among healthy non-risk individuals178–183. However, in Africa PARV4 
is spread differently. For example, in rural areas of Ghana with low HIV prevalence in the 
population, PARV4 DNA has been detected in blood, nasal swabs and fecal samples of 
young children indicating fecal oral or respiratory routes of infection184–186. In addition, 
in Burkina Faso, Cameroon, Congo, Botswana and South Africa, the seroprevalence 
between healthy adults (4-38%) and risk groups (HIV or HCV positives, 19-64%) differs 
less from each other than in Europe183,187–189. Here we did not analyze samples from 
HIV/HCV-positive patients or other risk groups in Finland or in the USA, and further 
studies are needed to elucidate, does BuV or CuV have such parenteral infection routes in 
the Northern hemisphere as PARV4.
In addition, although the antibody results cannot be compared to detection of viral 
DNA, it could be pointed out that in the study of rhesus macaques experimentally infected 
with SIV, the DNA of BuV-like virus (WUHARV parvovirus) was detected more often in 
the feces of SIV-infected animals than in healthy controls (29% vs. 2%, Table 1)146. 
However, these monkeys did not receive any medication for SIV, and developed 
symptoms and AIDS rapidly shown by the fact that nearly half of the animals needed to 
be euthanized before week 64 post infection due severe AIDS. In our IgG study the 
samples from the HIV positive patients were collected at the local HIV clinics, and 43/47 
were reported to receive HAART thus indicating that the HIV infection was under control. 
In all, BuV (or CuV) could cause more infections in AIDS patients, but based on our data 
on antibody prevalence, the HIV patients do not seem to be a specific risk group.
Table 8. BuV, TuV and CuV IgG seroprevalences of HIV-positive and -negative individuals in
Kenya. The age ranges of the HIV-positive and -negative adult cohorts were matched to
exclude potential age-related bias.
Cohort n Median age,range Any BuV BuV1 BuV2 BuV3 TuV CuV
Adults,
HIV pos 38
46 y,
27-85 y
30
(78.9%*)
10
(26.3%)
18
(47.4%)
19
(50.0%) 0
1
(2.6%#)
Adults,
HIV neg 60
45 y,
27-82 y
45
(75.0%*)
17
(28.3%)
21
(35.0%)
30
(50.0%) 0
2
(3.3%#)
Children,
HIV pos 9
9 y,
4-17 y
2
(22.2%) 0 0
2
(22.2%) 0 0
Children,
HIV neg 98
5 y,
0.5-17 y
20
(20.4%)
3
(3.1%)
4
(4.1%)
18
(18.4%) 0
2
(2.0%)
*??P=0.669; #???=0.8922; y, year
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4.4 CUV IN CTCL AND TRANSPLANT PATIENTS, AND
HEALTHY ADULTS (IV)
Introduction. The presence of CuV DNA skin biopsies of CTCL patients was reported
already in the original CuV discovery paper, and later on, a Danish group described CuV
sequences in skin biopsy from a melanoma patient. CTCL represents a group of T-cell
malignancies that arise on the skin, and there are various subtypes of which mycosis
fungoides is the most common190. The etiology of CTCL is unknown, although several
studies have explored and suggested infectious causes (reviewed in 191).
To study the frequency and possible role of CuV in CTCL and other skin diseases, skin
biopsies both from healthy and/or malignant skin from 25 CTCL patients, 136 transplant
recipients and 98 healthy adults were analyzed. For CuV DNA detection, a CuV qPCR was
developed, and together with a new TuV qPCR, the PCRs were combined with BuV qPCR
to create a multiplex qPCR detecting the three human protoparvoviruses in a single run.
In addition to the DNA, BuV, TuV and CuV IgG was analyzed from serum samples of 42
CTCL, 124 transplant patients and 78 healthy adults.
CuV and TuV singleplex qPCR and BuV-TuV-CuV multiplex PCR design. For
CuV qPCR, an alignment including all known CuV and BuV sequences was manually
analyzed to pinpoint regions with similarity among CuVs and variability towards BuVs.
After careful in silico and in vitro testing, a primer pair and a probe amplifying a 91-nt
piece close to the end of VP2 of CuV were selected (Fig. 17). For TuV, only one sequence
was available, and the qPCR was designed based on the VP2 region of the virus. The final
TuV qPCR amplified 118 nucleotide long piece of VP2 area (Fig. 17).
For the multiplex qPCR, no dimers between the oligos from the three individual qPCR
were observed, neither in silico nor in vitro analysis.
Figure 17. Schematic illustration of BuV-TuV-CuV multiplex qPCR amplicon locations. Amplicon
length and fluorophores used in the probes are indicated. Genome based on BuV1, 
strain BF.96 (GenBank no. JQ918261).
Performance of the qPCRs. The singleplex CuV and TuV qPCRs as well as the BuV-
TuV-CuV multiplex PCR amplified the viral sequences in all 20 replicates of 10 copies/μl
of plasmid, and the sensitivity remained when 450 ng of human DNA per reaction (90
ng/μl of template) was added to the amplification reaction. For BuV singleplex qPCR,
which was set up already in Study I, the sensitivity and specificity testing was repeated
here for comparison as well as due to the increased annealing temperature (from 60°C to
62°C), and the results were identical to CuV and TuV qPCRs. Overall, the results indicate
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that the analytical sensitivity, or the limit of detection (LOD), of the singleplex and
multiplex qPCRs was less or equal to 10 copies/μl, both with and without human DNA.
The LOD was further studied by probit analysis (see Study IV supplementary material
for further information). The analysis showed the following sensitivities for singleplex
and multiplex assays, respectively: for BuV ~4 copies/μl and ~9 copies/μl, for CuV ~5
copies/μl and ~6 copies/μl, and for TuV ~10 copies/μl and ~5 copies/μl, (Supplementary
Fig. S1 in Study IV).
In the specificity testing, no amplification was seen of human DNA from several
cultured cell lines or from high copy number plasmids of other human parvo- or
polyomaviruses. Furthermore, no cross-amplification from high copy number plasmids
of BuV1-3, TuV or CuV plasmids occurred.
CuV DNA in skin biopsies. CuV DNA was detected in the skin samples of 4/25 (16.0%)
CTCL patients, and 4/136 (2.9%) transplant patients, whereas all 159 skin biopsies from
98 healthy adults were negative for CuV DNA. The difference of CuV DNA prevalence
between the CTCL and transplant patients as well as between the CTCL and healthy
adults, were statistically significant (P=0.00575 and P<0.0001, respectively, Pearson’s χ2
test).
In the CTCL cohort, all studied biopsies were from the cutaneous lymphoma lesion of
the patients. To study the presence of CuV DNA in other tissues, additional samples were
retrospectively obtained from the pathology archives from two CuV DNA-positive CTCL
patients. From one patient, C-15, two prostate samples were available, and from the other,
C-53, two lymph node, two prostate and eight skin samples, the latter including both non-
malignant and malignant skin (pre-CTCL, CTCL and melanoma), were available for
analysis. While the four prostate samples were CuV DNA-negative, CuV DNA was present
in all skin and lymph node biopsies of patient C-53. Of note, the other CuV DNA-positive
lymph node was sentinel to the prostate that did not harbor CuV DNA.
The highest CuV DNA quantities were observed in the CTCL lesions and in early CTCL
tissue (lymphocytic atypia) with the viral load of 3.4E+07 to 7.3E+o8 (per 1E+06 cells)
(Table 2 in Study IV).  The two melanoma biopsies had the lowest viral loads, 2.3E+02
and 7.2E+02 (per 1E+06 cells). The different CuV DNA-positive biopsies from the patient
C-53 had been taken between 2012 and 2015 demonstrating that the patient harbored
CuV DNA in his tissues at least for four years.
In the transplant cohort, CuV DNA was detected in four individuals (P-022, P-065, P-
108 and P-A). Patients P-022 and P-108 were CuV-DNA positive in healthy skin, and
these patients did not suffer from any skin malignancies (Table 9 and Table 2 in Study
IV). Patients P-065 and P-A had skin cancer: basal cell carcinoma and squamous cell
carcinoma, respectively. Both patients were CuV-DNA positive in all biopsies tested, and
the viral load was higher in the cancerous tissues compared to the healthy skin (Table 9
and Table 2 in Study IV). Overall, when the CuV DNA prevalence in malignant skin
biopsies (14.0%, 6/44) was compared with that in non-malignant skin biopsies (0.9%,
2/215), the difference reached statistical significance (P <0 .0001, Pearson’s χ2 test).
Results and discussion
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Table 9. CuV DNA and IgG results from transplant patients with CuV DNA detected in skin.
Adapted and modified from Study IV with permission.
Patient Tx date Samplingdate Sampling site
Mean CuV
DNA
quantity?
CuV IgG
OD value
Transplant and other
info
P-022 5.1.2003 5.1.2003 Serum NA 1.448 Liver tx
CuV IgG pos prior to tx,
and seropos for >10 years
28.1.2003 Serum NA 0.554
11.1.2013 Healthy skin 4.51E+03 -
11.1.2013 Serum Negative 2.165
P-065 2.12.1991 1.12.1991 Serum NA 3.135 Liver tx
CuV IgG pos prior to tx,
and seropos for >21 years
Diseased in 2015
30.12.1991 Serum NA 0.805
29.10.2013 Healthy skin 3.92E+01 -
29.10.2013 Basal cellcarcinoma 3.35E+03 -
29.10.2013 Serum Negative 1.477
P-108 2.10.2009 30.6.2009 Serum NA 1.978 Liver tx
CuV IgG pos prior to tx,
and seropos for >5.5
years
16.12.2014 Healthy skin 2.71E+03 -
30.1.2015 Serum Negative 1.241
P-A 26.8.1986
and
25.6.1997
Unknown Healthy skin 2.54E+02 - Kidney tx at both times
No serum available
Unknown
Pre-malignant
(carcinoma in
situ)
2.28E+03 -
Unknown Squamous cellcarcinoma 1.00E+04 -
?? per 1E+06 cells
NA, not analyzed; tx, transplant
To date, nine studies have reported analyses of CuV DNA, and in six studies CuV DNA 
was detected (including Study IV, Table 10). Of note, the NGS results of a CuV DNA-
positive Danish melanoma patient have been published twice, however, they are counted 
here as one139,192. The presence of CuV DNA in skin samples has been reported in five 
studies and the CuV prevalence varied from 0% to 17% with the highest prevalence in 
cancer biopsies from CTCL patients (16%, Study IV) and in skin swabs from HIV-positive 
subjects (17%)142 (Table 10).
In addition to Study IV and the study describing the discovery of CuV36, Kreuter et al. 
found CuV DNA in CTCL patients from Germany: CuV DNA was detected exclusively in 
MF patients (6/71, 8.5%), whereas all patients (n=59) with other types of primary 
cutaneous B- or T-cell lymphomas were negative, including 20 patients with MF variants 
(folliculotropic MF, pagetoid reticulosis or Sézary syndrome)141.
The CuV prevalence in the German study was lower (8.5%) than in Study IV (16%)141. 
Although there can be various explanations for the difference, one possibility could derive 
from the used methodology. The German study reported that all six CuV DNA-positive 
samples harbored 2.6-170 CuV DNA copies per cell, which is a relatively high load. In 
comparison, in Study IV only one CTCL sample had more than 1 CuV copy per cell (33.5 
copies per cell in C-53), whereas the remaining three CuV DNA-positive samples had low
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loads, 0.00003-0.01 per cell. The performance of the qPCR by Kreuter et al. was not
reported141, so its sensitivity and specificity could be lower than that in Study IV. The
analysis of the primers used by Kreuter et al. showed that the forward primer had
mismatches (0-2 nt) to the CuV sequences available in GenBank, which may cause lower
specificity or sensitivity of the assay (Fig. 18). In addition, as both studies used FFPE
samples and the FFPE procedure may degrade DNA, the differences in the fixation
process may lead to different DNA-detection rates.
Samples from CTCL patients have been analyzed by Bergallo et al. with PCR and
samples specifically from MF by Mollerup et al. with NGS143,192. Both, however, reported
negative results, but the negativity may again derive from less sensitive methods or from
the small sample size (n=11) in the latter study (Table 10).
Figure 18. CuV primers used by Kreuter et al.141 aligned with published CuV sequences. The
reverse primer is the reverse complement sequence of the primer. The three 
stars in the consensus sequence depicts the mismatch locations in the primer. The 
probe is not shown as the sequence was not published (locked nucleic acid probe No. 5 
produced by Roche). Dot (.), identical nt compared to the consensus sequence.
In Study IV, CuV DNA was detected in various skin biopsies in addition to the CTCL
biopsies. In two transplant patients, CuV DNA was present both in healthy and in
cancerous skin (basal cell or squamous cell carcinoma, Table 9). Furthermore, the CTCL
patient C-53 harbored CuV DNA also in melanoma, atypical moles and dermatofibroma
(benign), as well as in lymph nodes (Table 2 in Study IV). In line with Study IV, CuV has
been detected in melanoma biopsies in two other studies139,142. In contrast, all skin
samples from the healthy individuals in Study IV were CuV-DNA negative (n=98), but
3.8% (9/237) of the skin swabs from healthy individuals in Germany had CuV DNA.
Remarkably, in the same German study a CuV DNA prevalence of 17.1% (35/205) was
observed in skin swabs from HIV-positive individuals, which is also the highest CuV DNA
prevalence in any study. However, it is not known whether CuV is more prevalent among
the German HIV-positive patients in general or was the different sample type or sampling
place causing the higher CuV DNA prevalence.
In all, the results indicate that CuV DNA can be detected in various skin specimens,
including healthy and malignant skin as well as in lymph nodes, nevertheless, the role of
CuV in any cancer or other diseases needs further studies.
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Amplification of longer CuV fragment and CuV sequence analysis. All CuV
qPCR positive samples were re-amplified with another PCR yielding 583 nt amplicons
that included also the entire qPCR area. The longer amplicon was obtained from 6/7 of
the CuV qPCR-positive fresh tissues from transplant patients, but only from 5/14 of the
FFPE samples from the CTCL patients. It is known that formalin fixing degrades DNA,
and it is often difficult or sometimes even impossible to amplify longer DNA fragments
from FFPE tissues. Here all FFPE tissues with amplifiable 583 nt CuV DNA had very high
CuV titres ranging from 4.8E+06 to 7.3E+08 (per 1E+06 cells), whereas FFPE tissues
with CuV quantities of 2.3E+02 to 6.9E+05 (per 1E+06 cells) remained negative. In
contrast, from the fresh tissues the 583-nt amplicon was obtained from a tissue with a
CuV quantity as low as 3.9E+01 (per 1E+06 cells). In other words, viral load of one virus
copy per cell was required for successful amplification from the FFPE tissues, but the load
of several logs less was enough with the fresh tissues.
For the phylogenetic analysis the primer sites were removed, and the remaining 538
nt CuV sequence was used for analysis. The CuV sequences amplified from several tissues
of one individual were shown to be identical, regardless whether the CuV was derived
from healthy or (pre)malignant tissue. The result was the same in each of the three
patients with multiple biopsies (P-065, P-A and C-53). In contrast to the identical
sequences within each individual, the CuV sequences from different patients varied. No
phylogenetic clustering, based on the sample type (skin or stool) or the geographical
location of the patient harboring the virus, were seen when all available CuV sequences in
GenBank were analyzed with the new sequences from this study (Fig. 1 in Study IV).
The identical sequence observed in each tissue from an individual could suggest that
i) either there had not been any productive replication of the viral DNA in these tissues
and the virus had persisted since the primary infection, ii) or that virus persisted
elsewhere in the body, then replicated, and finally migrated to the skin only recently. It
needs to be kept in mind that only a 538-nt piece of the VP2 region was used for this
sequence comparison. A (nearly) full length genome of CuV should be amplified from
each tissue to confirm whether there are mutations in the genome that could indicate
active replication. However, with patient P-065, the serum sample corresponding to the
skin biopsy was PCR negative demonstrating that the patient was not viremic at the
sampling time.
BuV and TuV DNA in skin biopsies and the functionality of the multiplex
qPCR assay. BuV and TuV DNA was not detected in the skin samples of any cohort.
Although the lack of viral DNA in skin suggests that BuV and TuV are not persisting in
skin tissue after primary infection like B19V or CuV, the study should be repeated with
cohorts from endemic areas such as the Middle East or Africa (in the case of BuV). Among
the studied Finnish subjects there were only few BuV1-3 or TuV IgG positives (see next
chapter and Fig. 19), and thus the number of patients potentially harboring the viral DNA
would be very low. Therefore, further studies are needed to confirm whether BuV or TuV
can persist in skin tissue after primary infection.
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As none of the tested skin biopsies had BuV or TuV DNA, the functionality of the assay
amplifying the native single-stranded viral DNA from human samples was validated with
fecal supernatants known to be BuV or TuV positive (the nearly full-length viral
genomes34,35 and the VP2 genes for creating VLPs had been previously amplified from
these samples). By the novel multiplex qPCR, the BuV DNA quantities were very similar
to the quantities detected with the BuV singleplex qPCR in 2012 (Table 11). The multiplex
qPCR was also able to amplify TuV DNA from the TuV DNA-positive fecal supernatant.
These results demonstrated that the multiplex qPCR could amplify the native ssDNA of
BuV and TuV in human samples, and hence, the negative results from the skin biopsies
were most likely caused by the true negativity of the samples instead of inadequate assay.
Table 11.  Quantitative PCR results of BuV and TuV DNA-positive human fecal samples.
Reproduced from the supplementary material of Study IV with permission.
Analysis year, method 2012, Singleplex qPCR 2017, Multiplex qPCR
Virus Sample copies/ml copies/ml
BuV1 BF7 4.94E+03 1.72E+03
BuV1 BF86 8.12E+03 1.93E+03
BuV1 BF96 4.95E+04 1.38E+04
BuV2 BF39 3.74E+03 2.90E+03
TuV Tu491 ND 4.22E+04
ND, not done; ml, milliliter of fecal supernatant.
BuV and CuV IgG prevalence in CTCL and transplant patients and in healthy
adults. CuV IgG was the most prevalent in each cohort, whereas BuV1-3 IgG findings
were less common or absent (Fig. 19). The CuV IgG prevalence was highest in the CTCL
cohort (9.5%, 4/42), followed by the transplant cohort (6.5%, 8/124) and the healthy
adults (3.8%, 3/78). Among the CTCL patients two patients had BuV1 IgG (4.8%, 2/42),
while among the transplant recipients one patient had BuV1 IgG, one BuV2 IgG and one
BuV3 IgG making the overall BuV-IgG prevalence of the cohort 2.4% (3/124) (Fig. 19).
Figure 19. IgG seroprevalence of BuV1-3, TuV and CuV in different adult cohorts in Finland.
“Veterinarians” is the same cohort than “Finland” in figure 16. The “any BuV” bar indicates
the persons harboring BuV IgG towards one or more BuV types.
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Nearly all seropositive individuals in these three cohorts had IgG towards a single
protoparvovirus or virus type; only one transplant patient had IgG towards both BuV1
and CuV. None of the seroprevalence differences between the three cohorts were
statistically significant. The IgG prevalences were also similar to the prevalence observed
among veterinarians in Finland (4.9% for CuV and 1.9% for BuV) in Study III (Fig. 19).
Longevity and fluctuations of BuV and CuV IgG in immunosuppressed
patients. From the transplant patients with BuV, TuV and/or CuV IgG detected in the
original serum sample (n=10), additional serum samples were obtained from the archives
and analyzed for protoparvovirus IgG. Archived serum samples were obtained also from
the transplant patient P-108, with CuV DNA-positive skin, but who lacked the initial
corresponding serum sample. Of these 11 patients (Table 12 and Table 4 in study IV), eight
had the first available sample taken before or on the day of the organ transplant surgery,
demonstrating the serological status of the patient prior to immunosuppression.
The EIA showed that five out of seven initially CuV IgG-positive subjects as well as the
CuV DNA-positive patient P-108 harbored CuV IgG already before or on the day of organ
transplantation (Table 12 and Table 4 in study IV). In addition, these patients remained
CuV IgG positive for 5 to 21 years despite moderate immunosuppression (Table 12). As
most of these patients were CuV IgG seropositive already in samples collected in 1991 or
in 2001-2003, shows that these individuals had been infected with CuV in the early 2000,
in 1990s or even before. This indicates that CuV has been circulating for a long time
although it was described for the first time in 2016. Whether the individuals were infected
with CuV in Finland or elsewhere, for example when travelling, cannot be defined based
on the current data.
One patient (P-093) seroconverted to CuV during immunosuppression (Table 12).
From patient P-060 a pre-transplantation serum sample was not available, however,
samples taken 8 and 19 years after the organ transplantation were both CuV IgG positive.
In patient P-055, who was TuV-IgG positive, the sample collected three days post-
transplantation showed CuV IgG with a low OD. However, the follow-up samples from
this patient were CuV IgG negative, and thus it can be hypothesized that this transient
positivity could have been passively derived from blood products instead from a true
infection. The TuV IgG positivity of this patient is discussed later in detail.
BuV1, BuV2 and BuV3 showed similar results to CuV: the BuV IgG-positive patients
were BuV-IgG positive already before the transplantation and they remained seropositive
for up to 11 years (Table 13 and Table 4 in study IV). The detection of long-lived BuV IgG
is in line with our previous results that IgG can be detected in an individual for years (see
chapter 4.2, results from Study II). Of note, the BuV1 IgG-positive patient was also CuV-
IgG positive, and with both viruses the IgG was detected on the day of the transplantation
as well as 9 years later, although with lower OD values.
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Table 12. Longevity of CuV IgG in the transplant-patient cohort. The IgG EIA results from follow-
up samples taken at variable time points from the CuV sero- and/or genopositive patients.
All positive results were confirmed with the competition assay. Negative IgG results (OD
values) are illustrated with italics. Reproduced and modified from Study IV with
permission.
Patient Transplant date Sampling date Age duringsampling
CuV IgG OD
value Longevity of IgG
P-022 5.1.2003 5.1.2003 63 y 1.448
28.1.2003 63 y 0.554
11.1.2013* 73 y 2.165 10 y
P-065 2.12.1991 1.12.1991 47 y 3.135
30.12.1991 47 y 0.805
29.10.2013* 68 y 1.477 almost 22 y
P-108? 2.10.2009 30.6.2009 49 y 1.978
30.1.2015 55 y 1.241 5.5 y
P-012 14.11.2002 3.11.2002 40 y 0.415
1.12.2002 40 y 0.336
3.12.2012 50 y 0.117 10 y
P-037 7.3.2001 7.3.2001 42 y 1.256
27.3.2001 42 y 0. 830
13.3.2013 54 y 0.829 12 y
P-018? 21.11.2003 21.11.2003 44 y 0.352
31.12.2012 53 y 0.155 9 y
P-060 10.4.1994 27.11.2002 61 y 0.815
9.10.2013 72 y 0.660 almost 11 y
P-093 1st tx 19.3.1996;
2nd tx 26.8.1997
14.4.1997 58 y 0.028 The patient had
seroconverted
during follow up
25.8.1998 60 y 0.044
23.9.1998 60 y 0.030
12.3.2014 75 y 0.294
P-055 12.8.2001 15.8.2001 36 y 0.232¤
See table 14 28.2.2003 37 y 0.019
24.9.2013 48 y 0.030
*, CuV DNA was detected in the skin biopsy taken at same time than serum sample
?, the patient had CuV DNA in skin biopsy taken 16.12.2014, but no corresponding serum was available?
?, the patient was also BuV1 IgG positive in both samples (see Table 13)
¤, IgG derived most likely from the blood transfusions/blood products, see text
Table 13. Longevity of BuV IgG in the transplant-patient cohort. The IgG EIA column shows the
OD values of the EIA for the virus mentioned in the first column. All positive results were
confirmed with the competition assay. Negative IgG results (OD values) are illustrated
with italics. Reproduced and modified from Study IV with permission.
Virus Patient Transplant date Sampling date Age duringsampling
IgG OD
value
Longevity of
IgG
BuV1 P-018? 21.11.2003 21.11.2003 44 y 2.066
31.12.2012 53 y 0.578 9 y
BuV2 P-034 11.3.2007 20.12.2006 58 y 0.169
21.4.2007 58 y 0.085
5.3.2013 64 y 0.168 6 y
BuV3 P-070 4.4.2002 23.2.2002 59 y 0.333
17.5.2002 59 y 0.120
12.11.2013 71 y 0.229 11.5 y
?, the patient was also CuV IgG positive in both samples (see Table 12)
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In several cases a drop in IgG OD values was observed when comparing the sample
taken before or at the time of transplantation with the sample taken 3-6 weeks after. Six
such sample pairs were available (patients P-022, P-065, P-012, P-037 for CuV; P-034 for
BuV2; and P-070 for BuV3, Tables 12 and 13), and in all the drop was apparent. The drop
could be due to the immunosuppressive medication the patients receive after
transplantation or to blood products. Because these virus infections are relatively
infrequent in Finland, such drop after the transplantation and the recovery of the IgG
level afterwards is easy to observe as the transfused blood is more likely to be
protoparvovirus IgG negative and would not interfere with the results. In contrast, when
analyzing the same samples for B19 IgG, a very prevalent parvovirus in Finland, the
observed IgG fluctuations varied greatly (unpublished data).
TuV IgG prevalence in CTCL and transplant patients and in healthy adults,
and longevity of the observed antibodies. Among the three cohorts containing 245
subjects with available serum samples, one individual harbored TuV IgG: transplant
patient P-055 was TuV-IgG positive in two consecutive samples taken over 10 years apart
(Table 14). Due to the rarity of the finding, the analysis was repeated with two different
TuV antigen batches, nevertheless, the results were identical from both samples and
indicated that this individual truly was TuV-IgG positive (Table 14).
In addition to the two serum samples with TuV IgG, a third serum sample was
available from the same patient, however, no TuV IgG was detected (Table 14). This
sample was taken three days post transplantation and 1.5 years before the first TuV IgG-
positive serum sample. The negative result could be explained in two ways. First, it is
possible that the patient was truly TuV-IgG negative at the time and seroconverted during
the next 1.5 years. The second explanation could be that if the patient was TuV-IgG
positive with a low titre before the surgery, the TuV IgG level three days post-surgery
Table 14.  Competition assay results from TuV IgG-positive transplant patient P-055. When the
OD value without blocking is <0.1, the sample is considered negative (marked with *). The
patient received a liver transplant 12.8.2001. The specific blocking is illustrated with
bolded numbers.
Sampling time 15.8.2001# 28.2.2003 24.9.2013
Antigen in the
well
TuV,
b1
TuV,
b2 CuV
TuV,
b1
TuV,
b2 CuV
TuV,
b1
TuV,
b2 CuV
Bl
oc
ki
ng
 a
nt
ig
en
none 0.055* 0.087* 0.218 0.355 0.462 0.019* 0.308 0.370 0.030*
BuV1 0.068 0.060 0.234 0.331 0.443 ND 0.287 0.356 ND
BuV2 0.055 0.064 0.217 0.177 0.244 ND 0.175 0.234 ND
TuV, b1 0.072 0.054 ND 0.052 0.020 ND 0.044 0.034 ND
TuV, b2 0.079 0.031 ND 0.084 0.024 ND 0.066 0.034 ND
CuV ND ND 0.045 ND ND ND ND ND ND
H5 0.048 0.039 0.209 0.457 0.601 ND 0.378 0.505 ND
*, negative; #, the sample was taken three days post-transplant surgery during which the patient received blood transfusions.?
b1, TuV VLP batch 1; b2, TuV VLP batch 2; H5, HighFive insect cell lysate; ND, not done
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could have been too low to be detected due to  immunosuppressive medication. Such post-
transplant drops in the IgG OD values of other viruses were observed in several transplant
patients as discussed earlier. In addition, the TuV IgG negative sample contained CuV
IgG, which was hypothesized to be derived from the blood transfusions as it was not
detected in the follow up samples of P-055 (Tables 12 and 14). This transient positivity
further shows that the antibodies detected in the sample most likely represented
antibodies from the blood donor instead of the patient.
Nevertheless, to date, this is only the second time (a child in Study II being the first),
when TuV IgG has been detected in an individual, and the first time ever, when longevity
of TuV IgG has been documented.
CuV DNA and IgG correspondence. In this study, there were three patients (P-022,
P-065 and P-108) harboring both CuV DNA and IgG. In each case, both the first serum
sample, taken 5-21 years before the CuV DNA-positive skin biopsy, as well as the last
serum sample, corresponding to the biopsy (or 6 weeks later in the case of P-108), were
CuV-IgG positive (see also Fig. 21 for P-065). This suggests that CuV antibodies are long-
lived, and that CuV DNA can persist for years, despite circulating antibodies, after acute
infection similarly to that of B19V.
In addition to the above-mentioned three patients, there were ten patients with CuV
IgG, but with no CuV DNA detected in the skin: two in the CTCL cohort, five in the
transplant cohort and three in the healthy adults cohort. Thus, CuV DNA was detected in
the skin of only 3/13 CuV IgG-positive subjects. With B19V, the correlation of sero- and
genopositivity has been shown to be close to 100% when sensitive and specific IgG EIA
and PCR assays are used50,62. So why were there many CuV DNA-negative individuals
among the seropositives?
1. Sampling place. Already in 2016, it was shown by in situ hybridization that the CuV
DNA-positive skin harbored very few, although strongly CuV positive cells36. In addition,
a recent article described the presence of CuV in the superficial layer and surface of the
skin, but not in deeper regions142. These findings point to that CuV is most likely not
evenly distributed in the skin, and thus the sampling site might have a tremendous effect
on CuV DNA detection and could explain some of the CuV DNA-negative findings in
seropositive individuals.
2. Sample type. As CuV was discovered only recently, the permissive cell(s), symptoms
during acute infection, the course of infection and development of immunity and
persistence are not known. Although CuV DNA has been detected in skin of several
individuals, the main place of persistence might be elsewhere in the body or for example
in a migrating cell such as T cells or B cells. CuV could end up in skin only during certain
conditions, for example in cancer, either as an infectious virus particle through the blood
supply or as viral DNA inside a migrating cell.
3. Variability of immune responses to acute infection. The immune response towards
CuV might vary between infected individuals, and it could be possible that in some
Results and discussion
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individuals, the immune system would not eradicate CuV after primary infection and
therefore the virus persisted. Although such a phenomenon has not been observed among
human parvoviruses, in other virus families this does play a role. For example, hepatitis
C virus infection may be spontaneously cleared in some people, but others develop
chronic infection.
4. Used methods. The CuV qPCR developed in Study IV was shown to be very sensitive
and specific for CuV, nevertheless it is possible that samples with very low virus loads can
remain negative. There can also be unknown CuV strains with mutations at the primer
and probe sites, which can lead to no or reduced amplification. In this study, CuV
sequences with a mismatch in the region of the 5’ end of the forward primer were detected
by the longer 583-nt PCR from several patients (Supplementary Fig. S2 in Study IV).
Although this mismatch was located in the noncritical end of the primer, it demonstrates
that there can be mutations in the amplified region.
CuV and BuV2 IgG cross-reactivity. In Study III, the interpretation of the
competition EIA results between the cross-reactive CuV and BuV2 IgG was established.
Analysis of samples from different cohorts demonstrated that the competition assay was
able to distinguish cross-reactivity of these two viruses, exemplified by three samples
from the Kenyan cohort presented in Table 7. Here, the original interpretation was further
strengthened by the blocking results from the three patients harboring both CuV DNA
and IgG: all competition assay results were identical to those in Study III. The CuV IgG
reactivity was blocked completely with CuV and only lowered by BuV2, whereas BuV2 IgG
reactivity was blocked completely both with BuV2 and CuV (Table 15). In addition, the
identical competition assay results were obtained from all serum samples from these
three CuV DNA- and IgG-positive individuals showing that the blocking characteristics
and the antigen specificity could remain for over 21 years.
Table 15. BuV2 and CuV competition-assay results from the three patients harboring both
CuV DNA and IgG. In each sample the CuV IgG reactivity was blocked completely only
with CuV, whereas the BuV2 IgG reactivity was blocked completely with both BuV2 and
CuV. The numbers represent OD values from the IgG EIA, and blocking is illustrated with
bolded numbers.
Patient P-022 P-065 P-108
Sampling time 5.1.2003 11.1.2013* 1.12.1991 29.10.2013* 30.6.2009 30.1.2015#
Antigen in the
well BuV2 CuV BuV2 CuV BuV2 CuV BuV2 CuV BuV2 CuV BuV2 CuV
Bl
oc
ki
ng
 a
nt
ig
en
none 0.799 1.546 1.166 1.970 0.880 2.458 0.317 1.206 1.410 2.000 0.529 1.142
BuV1 0.816 1.504 1.143 1.864 0.900 2.442 0.325 1.139 1.393 1.962 0.494 1.158
BuV2 0.025 0.590 0.011 0.833 0.033 1.651 0.018 0.477 0.045 0.929 0.016 0.597
CuV 0.026 0.018 0.014 0.012 0.026 0.027 0.019 0.017 0.043 0.031 0.016 0.014
*, Corresponding sample to the CuV DNA-positive skin biopsy; #, sample taken six weeks after the CuV DNA-positive skin biopsy
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5 CONCLUDING REMARKS AND FUTURE
PROSPECTS
In the beginning of the 21st century, the development of next generation sequencing
methods revolutionized the identification of novel viruses from various sample materials.
By using NGS, the amount and quality of sequence data increased tremendously, and the
decreasing price made large-scale screening possible. However, the detected sequence
itself provides only limited information on the properties of the virus, and thus further
studies are needed to transfer the data from the computer into biological functions.
In this thesis, the epidemiology and clinical picture of three novel human parvoviruses
were studied. Methods for DNA detection and quantification as well as for IgG antibody
detection were developed and samples from altogether eleven cohorts were analyzed. The
sample material included fecal samples from >1500 patients, nasal swabs from 955
children, and tissue biopsies from 260 individuals, all analyzed by qPCR, as well as serum
samples from nearly 1500 individuals ranging four continents, analyzed by IgG EIA.
One of the major findings of the thesis was the remarkable difference in BuV
seroprevalence observed between different geographical regions: in the Middle East and
Africa the BuV IgG antibodies were detected in 56-85% of the adult population whereas
in Finland and in the USA the seroprevalence was very low, <4% (Fig. 20). This indicates
that Iraq, Iran and Kenya are endemic areas for BuV infections. In addition, the IgG EIA
results of individuals from India suggested another endemic BuV area as well with high
seroprevalence, however, due to the low sample number (n=6, of which 3 had BuV1 IgG),
Figure 20. Global BuV IgG seroprevalence among adults. Combined seroprevalence of all BuV
types is indicated as well as the predominant BuV type. In Finland none of the BuV 
types were very common, and in India, there were only 6 individuals tested (see text).
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no clear conclusions could be made. The most prevalent BuV type varied as well, BuV1 
being the most frequent in the Middle East (and India), whereas BuV3 dominated in 
Kenya.
According to the competition assay, the three BuV genotypes seem to represent 
serotypes, although low-level cross-reactions were observed within the high prevalence 
cohorts. Whether that is a common phenomenon in the endemic areas, in which the 
circulating BuVs may boost the immunity continuously or a result of subsequent 
infections of the different BuV types or even with currently unknown BuV types, the 
answer requires longitudinal follow up studies in the area.
By qPCR, we found BuV DNA in ten fecal samples from patients with gastroenteritis 
symptoms in Finland (0.6%, 10/1584), however, our findings did not strongly support the 
role of BuV in gastroenteritis. The results were in line with other publications, and the 
current consensus seems to be that BuV circulates worldwide, but it is detected only 
occasionally in fecal samples, and clusters of patients with BuV infection have not been 
observed. To elucidate the symptoms and clinical picture of the BuV infection, the next 
important step will be to identify patients with acute primary infection. As we have 
identified endemic areas with high BuV seroprevalence, patients from those regions 
would be a logical starting point when addressing this question. Another important 
question will be, do the three BuV types differ from each other clinically like HBoV1 differs 
from HBoV2-4 or are the infections very similar like with B19V genotypes.
Regarding TuV, there has not been any publications with positive DNA findings since 
the discovery, and in this thesis, we found TuV IgG in only one child and one transplant 
patient, and both with low OD values. Therefore, it is still unknown, whether TuV truly is 
a human virus or just accidentally infecting or occasionally detected in humans.
CuV, on the other hand, showed different characteristics than BuV or TuV: although 
the seroprevalence was low (0-9.5%) in every analyzed cohort, the CuV DNA was detected 
in skin biopsies of CTCL and transplant patients in Finland. The CuV DNA prevalence in 
the CTCL patients (16%) was significantly higher than in the transplant patients (2.9%) 
or in the healthy adults (0%). Furthermore, CuV IgG was detected in serum samples 
taken over 21 years before the CuV DNA-positive skin biopsy (Fig. 21), which suggested 
that CuV DNA can persist in the body for decades after primary infection similarly to 
that of B19V. However, we found CuV DNA in the skin of only 3 out of 13 CuV 
seropositive individuals, and thus it might be that either the skin cells are not the major 
site for the persistence, or CuV is not persisting in every individual.
In general, parvoviruses are not considered oncogenic, but instead some are 
described as oncotropic and oncolytic, both of which have been reported for animal 
protoparvoviruses. For example, the rat protoparvovirus H-1 has a natural tropism for 
human cancer cells and it is currently investigated as a therapeutic agent for 
glioblastoma (reviewed recently in 145). However, only little is known of the molecular 
mechanisms and clinical impact of human parvovirus persistence in tissues. Are they 
inactive and dormant, or do they perhaps cause a long-term mild inflammation that 
could modify the host or immune cell activities. Previously, CuV has been detected by 
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Figure 21. Schematic time-line illustration of the CuV IgG and DNA observed in patient P-065.
CuV IgG was present already pre-tx with high OD (1.12.1991). One month post-tx a drop 
in the OD was observed, however, the IgG level recovered and was detected with high 
OD in 2013. CuV DNA was detected in both healthy and malignant skin in 2013. tx, 
liver transplantation
ISH only in a few, although strongly positive cells, in a CTCL biopsy36 and only in the 
surface layer of a melanoma142, which shows that the CuV is not present in every 
cancer cell. On the other hand, immunosuppression or other diseases may increase 
the risk of cancers associated with viruses, and thus the normally harmless virus 
persistence might turn into disease causing in the specific circumstances.  Overall, even 
if some preliminary disease associations exist, the role of CuV in CTCL or other skin 
cancers needs further investigations.
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